

# ARTHRITIS & RHEUMATISM

OFFICIAL JOURNAL OF THE AMERICAN RHEUMATISM ASSOCIATION  
SECTION OF THE ARTHRITIS FOUNDATION

## CONTENTS VOLUME 19, 1976

VOL. 19	JANUARY-FEBRUARY	No. 1
Electron Microscopic Observations of Immunoreactive Cells in the Rheumatoid Synovial Membrane <i>Hitoshi Ishikawa and Morris Ziff</i>	1	
Cutaneous Vessel Immune Deposits in Rheumatoid Arthritis <i>Doyt L. Conn, Arnold L. Schroeter, and Frederic C. McDuffie</i>	15	
Treatment of Psoriatic Arthritis with Azaribine <i>Seymour Levine and Harold E. Paulus</i>	21	
Presidential Address: Whither or Wither <i>Lawrence E. Shulman</i>	29	
Specific Detection and Semiquantitation of Microorganisms in Tissue by Nucleic Acid Hybridization <i>Charles R. Steinman and Konrad Hsu</i>	38	
Therapeutic Studies in NZB/W Mice <i>Michael C. Gelfand, Peter H. Schur, Richard Aszofsky, and Alfred D. Steinberg</i>	43	
Cyclophosphamide Protection in NZB/NZW Disease <i>Alan D. Morris, James Esterly, Gerald Chase, and Gordon C. Sharp</i>	49	
Current Comment: Geographic Distribution of Consultant Rheumatologists in the United States—1975 <i>Daniel J. McCarty</i>	56	
Experimental Hemarthrosis in the Knee of the Mature Canine <i>F. Richard Convery, Savio L-Y Woo, Wayne H. Akeson, David Amiel, and Lawrence L. Malcom</i>	59	
Current Comment: Recent Insights into the Pathogenesis of the Proliferative Lesion in Rheumatoid Arthritis <i>Edward Day Harris, Jr.</i>	68	
Reduction of Phagocytosis and Lysosomal Enzyme Release from Human Leukocytes by Serum from Patients with Systemic Lupus Erythematosus <i>Robert B. Zurier</i>	73	
Absent Factor II in Systemic Lupus Erythematosus <i>Ethan A. Natelson, Gerald S. Cyrus, and Robert A. Hettig</i>	79	
Dermatoglyphic Study of Systemic Lupus Erythematosus <i>Robert W. Dubois, John M. Weiner, and Edmund L. Dubois</i>	83	
Lymphocyte Responsiveness in Systemic Lupus Erythematosus <i>Peter D. Utsinger</i>	88	
Crystal Shedding and Acute Pseudogout <i>Robert M. Bennett, James R. Lehr, and Daniel J. McCarty</i>	93	

Hemarthrosis Associated with Sodium Warfarin Therapy <i>James H. Wild and Nathan J. Zvaifler</i> .....	98
Cryoimmunoglobulinemia in Felty's Syndrome <i>Michael Weisman and Nathan J. Zvaifler</i> .....	103
Coexistence of Ankylosing Spondylitis and Rheumatoid Arthritis <i>Harvinder S. Luthra, Richard H. Ferguson, and Doyt L. Conn</i> .....	111
Correlations Between Transaminase Concentrations and Serum Salicylate Concentration in Juvenile Rheumatoid Arthritis <i>John J. Miller III and David B. Weissman</i> .....	115
Perforation of Nasal Septum in Rheumatic Diseases <i>Robert F. Willkens, Gilbert J. Roth, Alvin Novak, and Joseph W. Walike</i> .....	119
Letters, Book Reviews .....	122
ARA Announcements .....	128

VOL. 19

MARCH-APRIL

No. 2

Histocompatibility Antigens in Systemic Lupus Erythematosus <i>Marc A. Goldberg, Frank C. Arnett, Wilma B. Bias, and Lawrence E. Shulman</i> .....	129
Antibody-Mediated Lymphocytotoxicity in Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>Efrain Diaz-Jouanen, Arthur D. Bankhurst, and Ralph C. Williams, Jr.</i> .....	133
Serum and Synovial Fluid Inhibitors of Antibody-Mediated Lymphocytotoxicity in Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>Efrain Diaz-Jouanen, Arthur D. Bankhurst, Ronald P. Messner, and Ralph C. Williams, Jr.</i> .....	142
Esophageal Varices in Felty's Syndrome: A Case Report and Review of the Literature <i>Raymond W. Klofkorn, James C. Steigerwald, David C. Mills, and Charley J. Smyth</i> .....	150
Effect of Aspirin on Liver Tests in Patients with RA or SLE and in Normal Volunteers <i>William E. Seaman and Paul H. Plotz</i> .....	155
Intraarticular Activation of the Complement System in Patients with Juvenile Rheumatoid Arthritis <i>Richard I. Rynes, Shaun Ruddy, Jocelyn Spragg, J. Sydney Stillman, and K. Frank Austen</i> .....	161
Acute Arthritis Caused by <i>Aeromonas Hydrophila</i> : Clinical and Therapeutic Aspects <i>Herman Chmel and Donald Armstrong</i> .....	169
Comprehensive Study of Humoral and Cellular Immune Abnormalities in 26 Patients with Systemic Amyloidosis <i>Morton A. Scheinberg and Edgar S. Cathcart</i> .....	173
Clinical Evaluation of Benzboromarone: A New Uricosuric Drug <i>Leif B. Sorensen and Dennis J. Levinson</i> .....	183
The Arthropathy of Relapsing Polychondritis <i>Michael O'Hanlan, Lawrence P. McAdam, Rodney Bluestone, and Carl M. Pearson</i> .....	191
Fibrinogen Catabolism in Systemic Lupus Erythematosus <i>John S. Sergent, Raymond L. Sherman, and Hamid Al-Mondhiry</i> .....	195
Metabolic Changes in Rabbit Articular Cartilage Due to Inflammation <i>Kalindi Deshmukh and Susan Hemrick</i> .....	199
Organization of Ground Substance Proteoglycans in Normal and Osteoarthritic Knee Cartilage <i>Kenneth D. Brandt and Marshall Palmoski</i> .....	209

Differentiation and Characterization of Autoantibodies and Their Antigens in Sjögren's Syndrome <i>Margaret A. Alspaugh, Norman Talal, and Eng M. Tan</i> .....	216
Antigenic Profile of the Rat Chondrocyte <i>Zoriana M. Malseed and Susan Heyner</i> .....	223
Carpal Arthritis with Ankylosis in Late Onset Still's Disease <i>Thomas A. Medsger, Jr., and Wallace C. Christy</i> .....	232
Clinical Rounds: Deforming Arthritis of the Hands in Polymyositis <i>Thomas W. Bunch, J. Desmond O'Duffy, and Richard A. McLeod</i> .....	243
Discussion: <i>Michael D. Lockshin</i> .....	247
Clinical Rounds: Lupus Erythematosus in a Patient with Amyloidosis, Adrenal Insufficiency, and Subsequent Immunoblastic Sarcoma: Demonstration of the LE Phenomenon in the Lung <i>L. A. Schleissner, William W. Sheehan, and Richard C. Orselli</i> .....	249
Discussion: <i>Edgar S. Cathcart and Morton A. Scheinberg</i> .....	254
Review: A Pathogenetic Model for Erosive Synovitis: Lessons from Animal Arthritides <i>Norton M. Hadler</i> .....	256
Letters .....	267
Books Reviews .....	270
ARA Announcements .....	274

VOL. 19

MAY-JUNE

No. 3 (Supplement)

**PART I: CLINICAL FEATURES**

Calcium Pyrophosphate Dihydrate Crystal Deposition Disease—1975 <i>D. J. McCarty</i> .....	275
Arthroscopic Findings of the Knee in Patients with Pseudogout <i>Roy D. Altman</i> .....	286
Pseudogout: Clinical Observations and Chemical Analysis of Deposits <i>Taro Okazaki, Terunobu Saito, Toshio Mitomo, and Yasuo Siota</i> .....	293
Roentgenographic Aspects of Calcium Pyrophosphate Dihydrate Crystal Deposition Disease (Pseudogout) <i>Harry K. Genant</i> .....	307
Destructive Arthropathy in Chondrocalcinosis Articularis <i>C. J. Menkes, F. Simon, F. Delrieu, M. Forest, and F. Delbarre</i> .....	329
Clinical Studies of Acute Pseudogout Attacks: Comments on Prevalence, Predispositions, and Treatment <i>J. Desmond O'Duffy</i> .....	349
Diseases Associated with CPPD Deposition Disease <i>E. B. D. Hamilton</i> .....	353
Discussion. Moderator: D. J. McCarty .....	358

**PART II: GENETICS**

Natural Course of Articular Chondrocalcinosis <i>D. Zitnan and S. Sitaj</i> .....	363
--	-----

HL-A System in Articular Chondrocalcinosis <i>S. Nyulassy, J. Stefanovic, S. Sitaj, and D. Zitnan</i> .....	391
Articular Chondrocalcinosis in the Chiloe Islanders <i>Antonio J. Reginato</i> .....	395
Articular Chondrocalcinosis in a Dutch Pedigree <i>Jan K. Van der Korst and Jos Geerards</i> .....	405
Discussion. Moderator: D. S. Howell .....	410

### PART III: PATHOLOGY AND CRYSTAL STUDIES

Ultrastructure Findings in Chondrocalcinosis and Pseudogout <i>H. Ralph Schumacher</i> .....	413
Articular Chondrocytes in Culture. Matrix Production and Hormonal Effects <i>Leon Sokoloff</i> .....	426
Discussion: Moderator: Dr. Dusan Zitnan .....	430

### PART IV: CRYSTAL STUDIES

Protein Adsorption to Monosodium Urate, Calcium Pyrophosphate Dihydrate, and Silica Crystals <i>Franklin Kozin and Daniel J. McCarty</i> .....	433
The Structural Basis of Crystal-Induced Membranolysis <i>Neil S. Mandel</i> .....	439
Calcium Pyrophosphate Crystal Chemistry <i>W. E. Brown and T. M. Gregory</i> .....	446
Discussion: Moderator: James Lehr .....	462

### PART V: METABOLISM

Metabolism of Inorganic Pyrophosphate (PP <sub>1</sub> ) <i>R. G. G. Russell</i> .....	465
Inorganic Pyrophosphate and Proteoglycan Metabolism in Cultured Human Articular Chondrocytes and Fibroblasts <i>G. Lust, G. Nuki, and J. E. Seegmiller</i> .....	479
Pyrophosphate Release by Osteoarthritis Cartilage Incubates <i>David S. Howell, Ofelia Muniz, Julio C. Pita, and Jerry E. Enis</i> .....	488
Preliminary Observations on Phosphatases in Articular Cartilages <i>David S. Howell, Ofelia Muniz, Julio C. Pita, and Charalampos Arsenis</i> .....	495
Discussion: Moderator: R. G. G. Russell .....	499
Author Index .....	501
Subject Index .....	502

Altered Lymphocyte Reactivity in Rheumatoid Arthritis <i>H. Arthur Silverman, John S. Johnson, John H. Vaughan, and James C. McGlamory</i>	509
Hereditary C2 Deficiency: Association with Skin Lesions Resembling the Discoid Lesion of Systemic Lupus Erythematosus <i>Richard Stern, Shu Man Fu, Merilena Fotino, Vincent Agnello, and Henry G. Kunkel</i>	517
Induction of Peripheral Blood Lymphocyte Transformation by Autologous Synovial Fluid Lymphocytes and Synovial Fluid <i>James E. Crout, Frederic C. McDuffie, and Roy E. Ritts, Jr.</i>	523
Mixed Leukocyte Reaction in Rheumatoid Arthritis <i>Edward C. Keystone, Dafna D. Gladman, Murray B. Urowitz, David A. Clarke, Judy A. Falk, David Osoba, and Duncan A. Gordon</i>	532
Cellular Hypersensitivity in Rheumatoid Arthritis, Ankylosing Spondylitis, and Anterior Nongranulomatous Uveitis <i>E. J-M. A. Thonar and M. B. E. Sweet</i>	539
Immunologic Observations on 9 Sets of Twins Either Concordant or Discordant for SLE <i>Sidney R. Block, Michael D. Lockshin, John B. Winfield, Marc E. Weksler, Masakatsu Imamura, Robert J. Winchester, Robert C. Mellors, and Charles L. Christian</i>	545
Predominance of T Cells in the Lymphocytic Infiltrates of Synovial Tissues in Rheumatoid Arthritis <i>Arthur D. Bankhurst, Gunnar Husby, and Ralph C. Williams, Jr.</i>	555
Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis <i>Alexander S. Townes, James M. Sowa, and Lawrence E. Shulman</i>	563
Identification of Antibodies to Nuclear Acidic Antigens by Counterimmunoelectrophoresis <i>N. Kurata and E. M. Tan</i>	574
Fine Structural Analysis of Rabbit Synovial Cells. II. Fine Structure and Rosette-Forming Cells of Explant and Monolayer Cultures <i>Phoebe R. Krey, Morton A. Scheinberg, and Alan S. Cohen</i>	581
Inhibition of Denaturation of Human Gamma Globulin by a Mixture of L-Histidine, L-Cystine, and Copper, and its Clinical Implication in Rheumatoid Arthritis <i>Donald A. Gerber</i>	593
Rheumatoid Factor (Antigammaglobulin) in Women: Effects of Oral Contraceptive Use on Its Prevalence <i>Ernest E. Sponzilli, Savitri Ramcharan, and John Wingerd</i>	602
Periarticular Uptake of <sup>99m</sup> Technetium Diphosphonate in Psoriasis: Correlation with Cutaneous Activity <i>Thomas C. Namey and Leonard Rosenthal</i>	607
Antibodies to Native and Denatured Collagens in Sera of Patients with Rheumatoid Arthritis <i>Nicolaos A. Andriopoulos, Jiri Mestecky, Edward J. Miller, and Edwin L. Bradley</i>	613
Effect of Prophylactic Colchicine Therapy on Leukocyte Function in Patients with Familial Mediterranean Fever <i>Charles A. Dinarello, Michael J. Chusid, Anthony S. Fauci, John I. Gallin, David C. Dale, and Sheldon M. Wolff</i>	618
Obstructive Pulmonary Disease in Rheumatoid Arthritis <i>Ronald L. Collins, Robert A. Turner, A. Myron Johnson, Nancy O. Whitley, and Ross L. McLean</i>	623

Articular Manifestations of Hypertrophic Pulmonary Osteoarthropathy in Bronchogenic Carcinoma: A Clinical and Pathologic Study <i>H. Ralph Schumacher, Jr.</i> .....	629
Case Report: Genu Amoris <i>Robert S. Pinals</i> .....	637
Clinical Rounds: Hypertrophic Osteoarthropathy and Rheumatoid Arthritis: Simultaneous Occurrence in Association with Diffuse Interstitial Fibrosis <i>Stephen L. Schechter and Giles G. Bole</i> .....	639
Discussion: <i>H. Ralph Schumacher, Jr.</i> .....	643
Current Comment: A Uniform Database for Rheumatic Diseases <i>The Computer Committee of the American Rheumatism Association</i> .....	645
Letters .....	649
Book Reviews .....	651
ARA Announcements .....	654

VOL. 19

JULY-AUGUST

No. 4

Introduction to the Joseph J. Bunim Memorial Lecture <i>R. W. Lamont-Havers</i> .....	655
Joseph J. Bunim Memorial Lecture: HLA-B27 and the Inheritance of Susceptibility to Rheumatic Disease <i>D. A. Brewerton</i> .....	656
Allergy in Systemic Lupus Erythematosus <i>John A. Goldman, Grace Ann Klimek, and Rida Ali</i> .....	669
Combination Therapy with Naproxen and Aspirin in Rheumatoid Arthritis <i>Robert F. Willkens and Eugene J. Segre</i> .....	677
Hip Involvement in Ankylosing Spondylitis <i>Isaac L. Dwosh, Donald Resnick, and Michael A. Becker</i> .....	683
Prednisone and Azathioprine Compared to Prednisone Plus Low-Dose Azathioprine and Cyclophosphamide in the Treatment of Diffuse Lupus Nephritis <i>Ellen Ginzler, Herbert Diamond, Maria Guttadaura, and David Kaplan</i> .....	693
Lymphocytotoxic Antibodies in SLE Patients and Their Relatives <i>Inés Malavé, Rodolfo Papa, and Zulay Layrisse</i> .....	700
Clinical Studies of Antibodies Binding Polyriboadenylic Acid in Systemic Lupus Erythematosus <i>Rao J. Pillarisetty and Norman Talal</i> .....	705
Serum Antibody in Rheumatoid Arthritis Reactive with a Cell-Associated Antigen <i>Margaret A. Alspaugh and Eng M. Tan</i> .....	711

Lymphocyte Populations in Rheumatoid Arthritis <i>Arnold J. Rawson and T. C. Huang</i> .....	720
Antibody-Dependent Cell-Mediated Cytotoxicity in Rheumatoid Arthritis <i>Martin A. Ithuriz, Maria M. de E. de Bracco, Ana M. Pizzi, and Jorge A. Manni</i> .....	725
Serum Immunoglobulins, Rheumatoid Factor, and Pneumoconiosis in Coal Miners with Rheumatoid Arthritis <i>Thomas G. Benedek, Zbigniew A. Zawadzki, and Thomas A. Medsger, Jr.</i> .....	731
The Role of Osmic Acid in the Treatment of Immune Synovitis <i>Victor M. Goldberg, Ralph Rashbaum, and Jocelyn Zika</i> .....	737
Mononuclear Cells in Human Synovial Fluid <i>Roger B. Traycoff, Eliseo Pascual, and H. Ralph Schumacher, Jr.</i> .....	743
P-Component of Amyloid <i>Merrill D. Benson, Martha Skinner, Tsuranobu Shirahama, and Alan S. Cohen</i> .....	749
Identity of a Peritoneal Fluid Immunoglobulin Light Chain and the Amyloid Fibril in Primary Amyloidosis <i>Paul J. Block, Martha Skinner, Merrill D. Benson, and Alan S. Cohen</i> .....	755
Pericardial Tamponade in Juvenile Rheumatoid Arthritis <i>J. Scharf, J. Levy, A. Benderly, and M. Nahir</i> .....	760
Cardiovascular Abnormalities in the Marfanoid Hypermobility Syndrome <i>Deborah J. Cotton and Kenneth D. Brandt</i> .....	763
Carrageein-Induced Arthritis. I. The Effect of Intraarticular Carrageein on the Chemical Composition of Articular Cartilage <i>Dennis A. Lowther and Gerald C. Gillard</i> .....	769
Chronic Arthritis Due to <i>Mycobacterium Intracellulare</i> <i>Don E. Cheatum, Victor Hudman, and Stephen R. Jones</i> .....	777
Arthritis Rounds: Ascites as the Major Manifestation of Systemic Lupus Erythematosus <i>Jacob Bitran, Dennis McShane, and Michael H. Ellman</i> .....	782
Discussion: <i>Eugene V. Ball</i> .....	786
Proceedings of the 40th Annual Scientific Session of the American Rheumatism Association: Abstracts of Papers Presented .....	787
Letters .....	832
Book Reviews .....	834
ARA Announcements .....	836

Significance of Persisting Serologic Abnormalities in SLE <i>Robert W. Lightfoot, Jr., and Graham R. V. Hughes</i>	837
Lymphocytotoxic Antibody Activity in Cryoprecipitates from Serum of Patients with SLE <i>Nathan J. Zvaifler and Harry G. Bluestein</i>	844
Characteristics of Patients with Serum Antibodies to Extractable Nuclear Antigens <i>James H. Leibfarth and Robert H. Persellin</i>	851
Comparison of the Complement-Fixing Activity of Antinuclear Antibodies in Lupus Nephritis, Mixed Connective Tissue Disease, and Scleroderma <i>Michael Dean Parker and Robert A. Turner</i>	857
Study of Thymic Factors. II. Failure of Thymosin to Alter the Natural History of NZB and NZB/NZW Mice <i>M. Eric Gershwin, Alfred D. Steinberg, Aftab Ahmed, and Craig Derkay</i>	862
Antibodies to dAT Detected by Membrane Filtration <i>Kenneth Lentz, John B. Winfield, and Peter Barland</i>	867
Lymphocyte Response to Mitogens in Progressive Systemic Sclerosis <i>Noel B. Salem and Jane H. Morse</i>	875
Association of Sjögren's Syndrome with HLA-B8 <i>Kenneth H. Fye, Paul I. Terasaki, Haralampos Moutsopoulos, Troy E. Daniels, Joseph P. Michalski, and Norman Talal</i>	883
Rheumatoid Factor in Acute Bacterial Endocarditis <i>John N. Sheagren, Carmelita U. Tuazon, Calvin Griffin, and Neville Padmore</i>	887
Connective Tissue Synthesis by Cultured Scleroderma Fibroblasts. I. In Vitro Collagen Synthesis by Normal and Scleroderma Dermal Fibroblasts <i>Jerome S. Perlish, Reza I. Bashey, Ralph E. Stephens, and Raul Fleischmajer</i>	891
Secondary Hypertrophic Osteoarthropathy: An Unusual Cause of Arthritis in Childhood <i>R. E. Petty, J. T. Cassidy, R. Heyn, A. G. Kenien, and R. L. Washburn</i>	902
Effects of Certain Antirheumatic Drugs on Normal Human Peripheral Blood Lymphocytes <i>Richard S. Panush</i>	907
Carrageenin-Induced Arthritis. II. Effect of Intraarticular Injection of Carrageenin on the Synthesis of Proteoglycan in Articular Cartilage <i>Gerald C. Gillard and Dennis A. Lowther</i>	918
Fibrous Myopathy: A Rheumatic Complication of Drug Abuse <i>Kent R. Johnson, Willa A. Hsueh, Sheldon M. Glusman, and Frank C. Arnett</i>	923
Intracellular Distribution of Radiogold: Localization to Large Granule Membranes <i>Neal S. Penneys, Sally McCreary, and Norman L. Gottlieb</i>	927
Effect of Fenoprofen Calcium on Acute Gouty Arthritis <i>Sunt Wanassukapunt, Yongsuk Lertratanakul, and Herbert M. Rubinstein</i>	933
Case Report: Gold Toxicity and Peritoneal Dialysis <i>Richard J. Combs, Mariellen M. Dentino, Linda Lehrman, and James J. Szwed</i>	936
Carpo:Metacarpal Ratio: A New Quantitative Measure of Radiologic Progression of Wrist Involvement in Rheumatoid Arthritis <i>David E. Trentham and Alfonse T. Masi</i>	939
Association Between HLA and Cutaneous Necrotizing Venulitis <i>David Glass, Nicholas A. Soter, David Gibson, C. B. Carpenter, and Peter H. Schur</i>	945
Current Comment: Rheumatoid Vasculitis <i>David Glass, Nicholas A. Soter, and Peter H. Schur</i>	950

Clinical Rounds: Carcinomatous Polyarthritis: The Presenting Symptom of an Ovarian Tumor and Association with a Platelet Activating Factor	953
<i>Robert M. Bennett, Mark H. Ginsberg, and Sharon Thomsen</i>	953
Discussion: <i>Thomas G. Benedek</i>	958
Editorial	960
Book Reviews	960
Letters	962
ARA Announcements	972

---

VOL. 19	NOVEMBER-DECEMBER	No. 6 (Supplement)
22ND RHEUMATISM REVIEW		973-1236

---

VOL. 19	NOVEMBER-DECEMBER	No. 6
Coagulation Abnormalities in Rheumatoid Disease		
<i>Doyt L. Conn, Frederic C. McDuffie, Francis J. Kazmier, Arnold L. Schroeter, and Nora C. J. Sun</i>	1237	
The Lupus Anticoagulant		
<i>Michael Boxer, Leonard Ellman, and Angelina Carvalho</i>	1244	
Clinical Significance of Immune Deposits in the Skin in SLE		
<i>David Wertheimer and Peter Barland</i>	1249	
Frequency of Neoplasia in Systemic Lupus Erythematosus and Rheumatoid Arthritis		
<i>Robert B. Lewis, C. William Castor, Robert E. Knisley, and Giles G. Bole</i>	1256	
IgG Antilymphocyte Antibodies in SLE Detected by $^{125}\text{I}$ Protein A		
<i>Ralph C. Williams, Jr., Arthur D. Bankhurst, and Jean D. Montaño</i>	1261	
Lymphocyte Response to Virus Antigens in Systemic Lupus Erythematosus		
<i>Robert E. Wolf and Morris Ziff</i>	1271	
Repeatability and Objectivity of Various Measurements in Rheumatoid Arthritis: A Comparative Study		
<i>D. R. Eberl, V. Fasching, V. Rahlf, I. Schleyer, and R. Wolf</i>	1278	
Carrageenin-Induced Arthritis. III. Proteolytic Enzymes Present in Rabbit Knee Joints After a Single Intraarticular Injection of Carrageenin		
<i>Dennis A. Lowther, Gerald C. Gillard, Elsmaree Baxter, Christopher J. Handley, and Kathryn A. Rich</i>	1287	
Secretion and Localization of Cathepsin D in Synovial Tissues Removed from Rheumatoid and Traumatized Joints: An Immunohistochemical Study		
<i>A. R. Poole, R. M. Hembry, J. T. Dingle, I. Pinder, E. F. J. Ring, and J. Cosh</i>	1295	
Aggregation of Cartilage Proteoglycans. II. Evidence for the Presence of a Hyaluronate-Binding Region on Proteoglycans from Osteoarthritic Cartilage		
<i>Kenneth D. Brandt, Marshall J. Palmoski, and Elaine Perricone</i>	1308	

Hyaluronic Acid Produced by Human Synovial Fibroblasts: Effect of Polyinosinic-Polycytidylc Acid (Poly I:C) and Interferon <i>M. Yaron, I. Yaron, O. Smetana, E. Eylan, and M. Herzberg</i> .....	1315
Chrysotherapy: A Prospective Study <i>Norman O. Rothermich, Vol K. Philips, Waldemar Bergen, and Marvin H. Thomas</i> .....	1321
Serum Antibody Levels Against T Mycoplasmas in Two North American Indian Populations Predisposed to Spondylitis <i>Denys K. Ford and Elizabeth Henderson</i> .....	1328
Organic Brain Syndrome in Rheumatoid Arthritis Following Corticosteroid Withdrawal <i>Ved P. Gupta and George E. Ehrlich</i> .....	1333
Histochemical Investigation of Adjuvant-Induced Arthritis <i>Fred R. Nusbickel and Henry Troyer</i> .....	1339
Suppression of Autoimmunity in NZB Mice with Steroid-Sensitive X-Radiation-Sensitive Syngeneic Young Thymocytes <i>Robert O. Morton, Dawn G. Goodman, M. Eric Gershwin, Craig Derkay, Robert A. Squire, and Alfred D. Steinberg</i> .....	1347
Brief Communication: Physical Features of Patients with Ankylosing Spondylitis <i>Nourollah Parhami</i> .....	1351
Transfer of Spleen Cells from Young to Aging NZB × NZW F1 Hybrid Mice: Effect on Mortality, Antinuclear Antibody, and Renal Disease <i>Robert E. Wolf and Morris Ziff</i> .....	1353
Measuring Synovial Fluid Viscosity with a White Blood Cell Diluting Pipette: A Simple, Rapid, and Reproducible Method <i>Peter Hasselbacher</i> .....	1358
Hypothyroidism Presenting as a Polymyositis-Like Syndrome: Report of Two Cases <i>Marc C. Hochberg, Gerald M. Koppes, Corwin Q. Edwards, H. Verdain Barnes, and Frank C. Arnett, Jr.</i> .....	1363
Letters .....	1367
Book Reviews .....	1375
ARA Announcements .....	1376
Annual Indexes .....	1377

# AUTHOR INDEX

(Page numbers in *italics* refer to abstracts.)

## A

Abdin ZH, 803  
 Agnello V, 517  
 Agus B, 962  
 Ahmed A, 862  
 Akeson WH, 59  
 Alarcón-Segovia D, 125, 796  
 Alepa FP, 966  
 Ali R, 699  
 Al-Mondhiry H, 195  
 Alspaugh MA, 216, 711, 787  
 Altman RD, 1371  
 Amiel D, 59  
 Andiman WA, 824  
 Andriopoulos NA, 613, 800  
 Ansell B, 789  
 Armstrong D, 169  
 Arnett FC Jr, 129, 923, 1363  
 Arroyave CM, 787, 829  
 Asofsky R, 43  
 Auclair R, 788, 788, 831  
 Auld WHR, 1368  
 Austen KF, 161

## B

Baldassare A, 788, 788, 831  
 Ball EV, 786  
 Bankhurst AD, 133, 142, 555, 1261  
 Barland P, 867, 1249  
 Barnes HV, 1363  
 Barone R, 964  
 Bashey RI, 891  
 Bass JC, 788  
 Bastian D, 818  
 Baum J, 807  
 Baxter E, 1287  
 Becker MA, 683  
 Bell RAF, 1373  
 Benderly A, 760  
 Benedek TG, 731, 835, 958  
 Bennett JC, 653, 960, 1375  
 Bennett PH, 791  
 Bennett RM, 93, 789, 791, 810, 953, 963  
 Bensason ML, 833  
 Benson MD, 749, 789, 822, 822  
 Benya P, 793  
 Bergen W, 1321  
 Berman L, 813  
 Bernstein BH, 789, 822  
 Berry DC, 971  
 Bias WB, 129  
 Bitran J, 782

Block SR, 545  
 Bluestein HG, 805, 831, 844  
 Bluestone R, 191, 828, 833  
 Bobrove AM, 790  
 Bole GG, 639, 790, 1256  
 Boxer M, 1244  
 Bradley EL, 613  
 Brandt KD, 209, 763, 1308, 1367  
 Brauer D, 792  
 Braun WE, 804  
 Bresnihan B, 791  
 Brewer E, 807  
 Brewerton DA, 656  
 Brinkman JP, 809  
 Bromige M, 971  
 Brown DH, 1368  
 Brown MM, 269  
 Brown TMCP, 650  
 Broyles JT, 788  
 Buckelew J, 794  
 Buckingham RB, 816, 817  
 Bunch TW, 123, 243, 248  
 Bywaters EGL, 789

## C

Calabro JJ, 273  
 Caldwell JR, 806  
 Calin A, 791, 791  
 Callerame ML, 792  
 Canoso JJ, 820  
 Caperton EM, 792  
 Carpenter CB, 945  
 Carvalho A, 1244  
 Cassidy JT, 808, 902  
 Castor CW, 1256  
 Cathcart ES, 173, 254, 831  
 Cavallo T, 817  
 Chandler RW, 814  
 Chase G, 49  
 Chase PH, 964  
 Cheatum DE, 777  
 Cheung H, 793  
 Chmel H, 169  
 Christian CL, 545, 809  
 Christy WC, 232  
 Chused TM, 797  
 Chusid MJ, 618  
 Clark HW, 649  
 Clarke DA, 532  
 Cohen AS, 581, 755, 789, 820, 822, 822  
 Cohen J, 651  
 Cohn H, 811  
 Collier DH, 811  
 Collins RL, 623, 827  
 Combs RJ, 936  
 Condemi JJ, 792

Conn DL, 15, 111, 824, 1237  
 Convery FR, 59  
 Cordon R, 801  
 Cosh J, 1295  
 Cotton DJ, 763  
 Cottrell W, 793  
 Crout JE, 523  
 Crugnola A, 793  
 Cunningham NE, 1368  
 Cyprus GS, 79

## D

Dale DC, 618  
 Dale IM, 1373  
 Daniels TE, 883  
 Davis P, 793  
 Dayer J-M, 794  
 de Bracco MMdeE, 725  
 DeChatelet L, 827  
 Decker JL, 819  
 Deesomchock U, 824  
 Dehner LP, 792  
 DeHoratius RJ, 794  
 Dentino MM, 936  
 Derkay C, 862, 1347  
 de Seze S, 833  
 Deshmukh K, 199  
 DeWind LT, 797  
 Diamond HS, 693, 811  
 Diaz-Jouanen E, 133, 142  
 DiBartolomeo AG, 794  
 Dinarello CA, 618  
 Dingle JT, 1295  
 Dorfmann H, 833  
 Dornfeld L, 833  
 Dubois EL, 83  
 Dubois RW, 83  
 Durward WF, 123  
 Dwosh IL, 683, 795, 795

## E

Eberl DR, 1278  
 Edwards CQ, 1363  
 Ehrlich GE, 806, 1333  
 Eisenbeis CH, 823  
 Ellman L, 1244  
 Ellman MH, 782  
 Emery H, 795  
 Emori W, 796  
 Esdaile JM, 795  
 Esterly J, 49  
 Evans J, 802  
 Eylan E, 1315

## F

Falk JA, 532, 795

Fasching V, 1278  
 Fauci AS, 618  
 Faulkner CS II, 801  
 Feigenbaum SL, 814  
 Feigl P, 820  
 Ferguson RH, 111  
 Fernandez-Diez J, 812  
 Fernandez-Herlihy L, 832  
 Fink CW, 807  
 Fishbein E, 796  
 Fleischmajer R, 891  
 Foad BSI, 122  
 Ford DK, 1328  
 Forrester D, 789  
 Fotino M, 517  
 Fowler RS Jr, 795  
 Franck WA, 269  
 Freyberg RH, 271  
 Friou GJ, 797  
 Fritzsche H, 968  
 Fu SM, 517  
 Furst DE, 267, 796  
 Fye KH, 811, 883

## G

Galindo LF, 812  
 Gallacher A, 823  
 Gallin JI, 618  
 Gehle WD, 801  
 Gelfand MC, 43  
 Gerber DA, 593  
 Gershwin ME, 797, 862, 1347  
 Giangiacoma J, 831  
 Gibson D, 798, 945  
 Gillard GC, 769, 918, 1287  
 Gilliam JN, 797, 815  
 Ginsburg JH, 797, 953  
 Ginzler E, 693  
 Giuliano VJ, 791  
 Gladman DD, 532, 826  
 Glass D, 798, 817, 945, 950  
 Glauert AM, 801  
 Glinski W, 797  
 Glusman SM, 923  
 Goldberg LS, 828  
 Goldberg MA, 129  
 Goldberg VM, 737, 798, 798, 813  
 Goldenberg DL, 820  
 Goldman AL, 791  
 Goldman JA, 650, 669  
 Good AE, 1372  
 Goodman DG, 1347  
 Gordon DA, 532  
 Gottlieb NL, 927  
 Grady RF, 962  
 Gray RG, 1371

Green A, 806  
Greenwald RA, 799, 799  
Grelier JM, 800  
Griffin C, 887  
Grishman E, 824  
Gupta N, 267  
Gupta VP, 1333  
Guttadaura M, 693

## H

Hadler NM, 256  
Hague JM, 1372  
Hahn B, 800, 810, 826, 966  
Hahn T, 800  
Hamanishi C, 800  
Handley CJ, 1287  
Hanson V, 789, 807, 822, 825  
Hardin JG, 272, 800, 960  
Hargrave R, 816  
Harmon C, 801  
Harrington JT Jr, 801  
Harris ED Jr, 68, 801, 809, 812  
Harris ER, 814  
Harth M, 802  
Hasselbacher P, 802, 1358  
Hathaway DE, 792  
Hausknecht M, 810  
Held C, 801  
Hembry RM, 1295  
Hemrick S, 199  
Henderson E, 1328  
Herd JK, 1370  
Herzberg M, 1315  
Hess EV, 122, 645  
Hettig RA, 79  
Heyn R, 902  
Heyner S, 223  
Hochberg MC, 1363  
Horwitz DA, 802  
Hough A, 835  
Howard A, 789  
Howell DS, 961  
Hsu K, 38  
Hsueh WA, 923  
Huang TC, 720  
Hudman V, 777  
Hughes GRV, 837  
Hunder GG, 126, 803, 815  
Hunter T, 795  
Husby G, 555, 803, 821  
Hutchison RM, 793  
Hymes AJ, 813

## I

Imamura M, 545  
Ishikawa H, 1  
Isturiz MA, 725  
Ito T, 800

Jasin HE, 791, 803  
Jayson MIV, 971  
Jimenez FJ, 812  
Jimenez SA, 804  
Johnson AM, 623  
Johnson JS, 509  
Johnson KR, 923  
Jones SR, 777  
Jupiter J, 791  
Juul-Nielsen K, 802

## K

Kagen LJ, 804  
Kahn M-F, 833  
Kamel H, 1368  
Kaplan D, 693  
Kaplan SB, 814  
Kar NC, 267  
Katholi RE, 651  
Katz AL, 966  
Kaye JJ, 127  
Kazmier FJ, 1237  
Kenien AG, 902  
Kerby GP, 969  
Kettlekamp DB, 1367  
Keystone EC, 532  
Khan MA, 798, 804  
King KK, 789, 822  
Klimek GA, 669  
Kline S, 1371  
Klippen JH, 805  
Kloforn RW, 150  
Knisley RE, 1256  
Kolarz G, 968  
Kondo H, 805  
Koppes GM, 1363  
Kornreich HK, 789, 822  
Kozin F, 805  
Krane SM, 794  
Krey PR, 581  
Kunkel HG, 517  
Kurata N, 574  
Kushner I, 798, 804

## L

Laham MN, 806  
Lamont-Havers RW, 655  
Layrisse Z, 700  
Lazarus D, 799  
Lehr JR, 93  
Lehrman L, 936  
Leibfarth JH, 851  
Lentz K, 867  
Leon SA, 806  
LeRoy EC, 809  
Lertratanakul Y, 933  
Levine S, 21, 796  
Levinson DJ, 183  
Levinson JE, 807  
Levitin PM, 651

Levy J, 760, 807  
Lewis RB, 1256  
Lightfoot RW Jr, 837  
Lillard S, 801  
Lin T-Y, 829  
Lindamood M, 807  
Lippiello L, 127  
Lipsky PE, 808  
Litwin A, 122  
Lloyd-Jones K, 971  
Locke JD, 810, 963  
Lockshin MD, 247, 545  
Loehnen PE, 824  
Lowther DA, 769, 918, 1287  
Luthra HS, 111

## M

McAdam LP, 191  
McCarty DJ, 56, 93, 805  
McChesney LF, 825  
McCombs C, 811  
McCravey JW, 826  
McCreary S, 927  
McDuffie FC, 15, 270, 523, 803, 1237  
McGirr D, 802  
McGlamory JC, 509  
McGuire MB, 818  
Machleder HI, 814  
McKenna CH, 824  
McLean RL, 623  
McLeod RA, 243, 248  
McShane D, 782  
Maddison PJ, 808  
Magilavy DB, 808  
Mainardi C, 799, 809  
Malavé I, 700  
Malawista SE, 824  
Malcom LL, 59  
Malseed ZM, 223  
Mandell B, 823  
Mankin HJ, 652  
Manni JA, 725  
Maricq HR, 809  
Markenson JA, 809  
Mashburn H, 827  
Masi AT, 814, 826, 939  
Maurer K, 821  
Medoff ME, 810, 964  
Medsger TA Jr, 232, 731, 823  
Mehta J, 810  
Meisel AD, 811  
Mellors JW, 811  
Mellors RC, 545, 811  
Messner RP, 142, 794, 821  
Mestecky J, 613  
Metzger A, 796  
Michalski JP, 811, 883  
Miller B, 807  
Miller EJ, 613  
Miller J, 821  
Miller JJ III, 115

Miller P, 790  
Mills DM, 150, 807  
Milne R, 826  
Mintz G, 812  
Mitre BK, 823  
Mongan ES, 797  
Montaño JD, 1261  
Montoya HE, 791  
Morgan GJ Jr, 812  
Morris AD, 49  
Morse JH, 875  
Morton RO, 1347  
Moskowitz RW, 813  
Moutsopoulos H, 883  
Moy WW, 799, 799  
Mullinax F, 813  
Mullinax GL, 813  
Myers AR, 813, 828

## N

Nagai J, 800  
Nahir M, 122, 760, 1373  
Namey TC, 607  
Narins RG, 828  
Nasrallah NS, 814  
Nateelson EA, 79  
Newton CD, 970  
Nimni M, 793  
Nirenberg L, 1373  
Niwayama G, 818  
Novak A, 119  
Nusbickel FR, 1339  
Nyman KE, 814

## O

O'Brien WM, 791  
Ochs H, 820  
O'Duffy JD, 243, 248, 815  
Ogryzlo MA, 795, 795  
O'Hanlan M, 191  
Orselli RC, 249  
Osoba D, 532  
Ottaway JM, 1368

## P

Padmore N, 887  
Palmoski M, 209, 1308  
Pandya MR, 962  
Panush RS, 806, 907  
Papa R, 700  
Papoian R, 819  
Parhami N, 1351  
Parker DM, 827, 857, 969  
Pascual E, 743  
Paulus HE, 21, 267, 796, 814  
Pearson CM, 191  
Pennebaker J, 815  
Penney NS, 927  
Perez-Busquier M, 833  
Perlisch JS, 891

Perper RJ, 829  
 Perricone E, 1308  
 Persellin RH, 815, 825, 851  
 Petty RE, 808, 902  
 Philips VK, 1321  
 Phillips PE, 809, 816  
 Pillarisetty RJ, 705, 819  
 Pinals RS, 637  
 Pinder I, 1295  
 Pizzi AM, 725  
 Plotz PH, 155  
 Poland M, 806  
 Poole AR, 1295  
 Poss R, 834  
 Powell AE, 798, 798  
 Prince RK, 816, 817  
 Pritzker KPH, 817

**Q**  
 Quismorio FP, 797, 825

**R**  
 Rabin BS, 794, 805, 823  
 Radin E, 793  
 Rahlfis V, 1278  
 Ramcharan S, 602  
 Rashbaum R, 737  
 Raum D, 798, 817  
 Rawson AJ, 720  
 Reginato AJ, 821  
 Reichlin M, 808  
 Resnick D, 683, 818  
 Reyes PA, 818  
 Rich KA, 1287  
 Richards AJ, 650  
 Ring EFJ, 1295  
 Ritts RE Jr, 523  
 Robinson DR, 818  
 Rodnan GP, 794, 805, 816, 817  
 Rooney PJ, 819  
 Rosenberg D, 823  
 Rosenthal L, 607  
 Roth GJ, 119  
 Rothermich NO, 1321  
 Roubinian JR, 819  
 Rubinow A, 820  
 Rubinstein HM, 833  
 Ruddy, S, 161  
 Russell RGG, 794  
 Rynes RI, 161

**S**  
 Sakofsky Y, 791  
 Salem NB, 875  
 Sarkissian ES, 267  
 Schaller JG, 795, 807, 820, 820  
 Scharf J, 122, 760, 1373  
 Schechter SL, 639, 1372  
 Scheiderer LM, 790  
 Scheinberg MA, 173, 254, 581, 831  
 Scherak O, 968  
 Schiller A, 793  
 Schleissner LA, 249  
 Schleyer I, 1278  
 Schmid FR, 791  
 Schroeter AL, 15, 1237  
 Schumacker HR Jr, 629, 643, 743, 802, 813, 821, 827  
 Schunke P, 798  
 Schur PH, 43, 798, 817, 945, 950, 964  
 Schwartz HA, 1369  
 Seaman WE, 155  
 Searles RP, 821  
 Segre EJ, 677  
 Sergent JS, 195  
 Shapiro B, 806  
 Shapiro R, 818  
 Sharp GC, 49, 801, 830  
 Sheagren JH, 887  
 Sheehan WW, 249  
 Sherman RL, 195  
 Shirahama T, 749, 822  
 Shulman LE, 29, 129, 563  
 Silverman HA, 509  
 Sinclair N, 802  
 Singsen BH, 822  
 Skinner M, 749, 822, 822  
 Skosey JL, 789  
 Sledge CB, 828  
 Smetana O, 1315  
 Smith CA, 823  
 Smith KO, 801  
 Smith WE, 1368  
 Smyth CJ, 150  
 Smythe HA, 795, 795  
 Snydman DR, 824  
 Sorenson LB, 183  
 Soter NA, 817, 945, 950  
 Sowa JM, 563  
 Spiera H, 824  
 Spilberg I, 823, 966  
 Sponzilli EE, 267, 602  
 Spragg J, 161  
 Squire RA, 1347  
 Srinivasan R, 796  
 Starz TW, 823  
 Steere AC, 824  
 Steigerwald JC, 150, 807

Stein HB, 795, 795  
 Steinberg AD, 43, 797, 819, 862, 1347  
 Steinman CR, 38, 824  
 Stephens RE, 891  
 Stern R, 517  
 Stevens MB, 1375  
 Stewart A, 1367  
 Stewart E, 816  
 Stiller CR, 802  
 Stillman JS, 161, 798, 817  
 Stobie DG, 825  
 Stobo JD, 824  
 Sugarman M, 825  
 Sukhupunyaraksa S, 791, 810, 963  
 Sullivan DB, 808  
 Sun NCJ, 1237  
 Sweet MBE, 539  
 Szwed JJ, 936

**T**  
 Takeuchi A, 825  
 Talal N, 216, 705, 811, 819, 883, 964  
 Tan EM, 216, 574, 711, 787, 787, 818, 822, 829  
 Tan RF, 826  
 Tanphaichitr K, 826, 966  
 Terasaki PI, 791, 811, 883  
 Thoi LL, 815  
 Thomas ED, 820  
 Thomas MH, 270, 1321  
 Thomsen S, 953  
 Thonar EJ-MA, 539  
 Tolchin SF, 823  
 Townes AS, 563  
 Traycoff RG, 743  
 Trentham DE, 826, 939  
 Troyer H, 1339  
 Tsai C, 788, 831  
 Tse R, 821  
 Tuazon CU, 887  
 Tudor RB, 651  
 Turner RA, 623, 827, 857

**U**  
 Urowitz MB, 532, 795, 795  
 Utsinger PD, 88, 818, 827

**V**  
 Van de Rijn I, 803  
 Van Linder S, 828  
 Vater CA, 809  
 Vaughan JH, 509, 829

**W**  
 Wahner H, 815  
 Walike JW, 119  
 Wallace SL, 964  
 Wanassukapunt S, 933  
 Washburn RL, 902  
 Wedgwood RJ, 820, 820  
 Weiner JM, 83  
 Weisbart RH, 828  
 Weisberg JW, 828  
 Weisman M, 103  
 Weiss T, 788, 788  
 Weissel M, 968  
 Weissman DB, 115  
 Weksler ME, 545  
 Werb Z, 809  
 Wertheimer D, 1249  
 Whitley NO, 623  
 Wild JH, 98  
 Williams HR, 829  
 Williams RC Jr, 133, 142, 555, 803, 1261  
 Willkens RF, 119, 677, 791  
 Wilson MR, 829  
 Wilson SE, 830  
 Winchester RJ, 545  
 Winfield JB, 545, 867  
 Wingerd J, 602  
 Wolf R, 1278  
 Wolf RE, 1271, 1353  
 Wolfe JF, 801, 830  
 Wolff SM, 618  
 Woo SL-Y, 59

**Y**  
 Yamasaki K, 830  
 Yaron I, 1315  
 Yaron M, 1315  
 Yonkosky D, 831  
 Yount WJ, 827

**Z**  
 Zabriskie J, 803  
 Zawadzki ZA, 731  
 Ziff M, 1, 791, 808, 815, 830, 1271, 1353  
 Zika J, 737  
 Zuberi R, 802  
 Zuckner J, 788, 788, 831  
 Zurier RB, 73  
 Zvaifler NJ, 98, 103, 805, 831, 844

## SUBJECT INDEX

### ARTHRITIS AND RHEUMATISM, Vol. 19, 1976

Page numbers in italics refer to abstracts. The *Conference on Pseudogout and Pyrophosphate Metabolism* (pp 275-508) and the *22nd Rheumatism Review* (pp 973-1237) are indexed separately.

#### A

Acetaminophen, 907  
lymphocytes and, 911  
Acetylsalicylic acid, 907  
lymphocytes and, 910  
Acetyl transferase activity, in SLE, 796  
Acute anterior uveitis, HLA antigens in, 660  
Acute lymphocyte choriomeningitis, 657  
Acute polyarticular gout, Ibuprofen in, 269  
Acute pseudogout, crystal shedding and, 93-97  
ADCC, *see* Antibody-dependent cell-mediated cytotoxicity  
Adenine/thymidine nucleotides, in <sup>14</sup>C-dAT, 867  
Adenosine triphosphatase, in adjuvant arthritis, 1340, 1342-1344  
Adjuvant arthritis, 257-259  
cartilage matrix histochemistry in, 1341-1343  
clinical description of, 257  
eruptive synovitis and, 256  
Freund's adjuvant in, 259  
gross and histologic alterations in, 1340  
histochemical investigation in, 1339-1345  
histopathology of, 258  
immunobiology of, 258-259  
wax D in, 259  
Adrenal insufficiency, in SLE, 249-252  
*Aeromonas hydrophilia*, in acute arthritis, 169-171  
Affinity chromatography, amyloid P-component separation with, 749-753  
Agammaglobulinemia, rheumatoid arthritis and, 555  
Allergic angiitis, 949  
Allergic disorders, defined, 669-670  
Allergy questionnaire, 670-671  
Allied Health Professions, 33  
American Cancer Society, 36  
American Heart Association, 36  
American Indian populations, ankylosing spondylitis in, 1328-1332  
American Rheumatism Association, 29-30, 97, 655  
Computer Committee of, 645-647  
proceedings of, 787  
*American Rheumatism Association Directory*, 56  
American Rheumatism Association Medical Information System, 646  
Amyloid  
Bence-Jones protein in, 173, 180  
deposition of, 173  
Amyloid fibrils  
isolation and purification of, 756  
in primary amyloidosis, 755-758  
Amyloidosis  
B-cell activation and macrophage dysfunction in, 831  
B-cell "escape" in, 254  
Bence-Jones proteins and, 173  
bovine thymic hormone in, 180  
concanavallin A and, 179  
defined, 173-174  
DNA synthesis in, 179-180  
hereditary, 174  
leukemia-lymphoma and, 174-177  
lymphocyte transformation studies in, 176-177

multiple myeloma and, 174-177  
primary, 174, 755-758  
serum and urine immunoglobulin abnormalities in, 175  
SLE and, 249-252  
thymosin in, 180  
Amyloid P-component, 749-753  
sequence analysis in, 822  
Amyloid P-component protein, 749-753  
Amyloid protein SAA levels, in JRA, 789  
ANA, *see* Antibodies to nuclear antigens  
Ankylosing hyperostosis, of spine, 818  
Ankylosing spondylitis  
in American Indians, 1328-1332  
axial migration in, 686-687  
case reports in, 111-112  
cellular hypersensitivity in, 539-543  
in childhood, 662  
coexistence with RA, 111-114  
definition of, 660  
hip involvement in, 683-692  
hip surgery in, 691-692  
HLA antigens and, 659-660  
HLA-B27 antigen in, 804-805, 883  
impairment of lymphocyte responsiveness in, 798  
life expectancy in, 689  
osteoarthritic controls in, 689  
penicillamine in, 122  
physical features of patients with, 1351-1352  
postoperative heterotopic ossification in, 690  
superior migration in, 686-688  
Ankylosis  
carpal arthritis and, 232-241  
in JRA, 240  
Anterior nongranulomatous uveitis, 539-543  
Antibodies  
identification of by counterimmunolectrophoresis, 574-579  
polyriboadenylic acid bonding of in SLE, 705-709  
to extractable nuclear antigens, 851-856  
to native and denatured collagens in RA, 613-616  
Antibodies to IgA, in rheumatic and pulmonary disease, 792  
Antibodies to nuclear antigens  
in mixed connective tissue disease, 574-575  
in Sjögren's syndrome, 574  
in SLE, 574, 786  
Antibody-dependent cell-mediated cytotoxicity in RA, 725-729  
Antibody-mediated lymphocytotoxicity, *see* Lymphocyte-dependent antibody toxicity  
Antibody response, to rat chondrocyte injection, 225  
Anticoagulant therapy, hemoarthrosis and, 99  
Anticollagen autoantibodies, in RA, 539  
Anticomplementary activity, in SLE, 74  
Anti-DNA, nephritis and, 49  
Anti-EI serum, 39  
Anti-ENA, *see* Extractable nuclear antigens  
Anti-gammaglobulins  
in RA, 613  
in women, 602-606  
Antigen-antibody complexes, in RA, 613  
Antigen pronestyl-human serum albumin, in SLE, 794  
Antigens

nuclear, *see* Nuclear antigens  
in twin SLE studies, 545-552

Antilymphocyte antibodies  
in SLE, 821  
in SLE twin studies, 549

Anti-nDNA antibodies, in SLE, 815, 867

Antinuclear antibodies  
complement-fixing, 857-860  
in Felty's syndrome, 105  
nonhistone nuclear protein and, 818  
in NZB mice, 1354-1355  
in polymyositis, 830  
in RA, 712  
in SLE, 702

Antirheumatic drugs, human peripheral blood lymphocytes and, 907-916

Anti-RNA antibody, in SLE, 1265

ANU, *see* Anterior nongranulomatous uveitis

Aortitis, 662

ARA, *see* American Rheumatism Association

Arachnodactyly, in Marfanoid hypermobility syndrome, 764

ARA Index, 1278, 1281, 1283

ARA Joint Count, 1278

Arboviruses, arthritis and, 1317

Arteritis  
digital, 19  
temporal, 812

Arthritides, erosive inflammatory, 256

Arthritis  
adjuvant, *see* Adjuvant arthritis  
*Aeromonas hydrophila* as cause of, 169-171  
azaribine in, 21  
avian reovirus and, 830  
B27 positive patients with, 820  
calcium pyrophosphate dihydrate induced, 823  
carpal, 232-241  
carrageenin-induced, 769-775, 918-921, 1287-1293  
childhood, *see* Childhood arthritis  
crystal-induced, 821  
degenerative, *see* Degenerative arthritis  
detection of organisms in, 38-42  
*Erysipelothrix*, *see* *Erysipelothrix* arthritis  
gonococcal, 826-827  
gouty, *see* Gouty arthritis  
of hands, in polymyositis, 243-248  
of knee, 637-638  
psoriatic, 651, 661, 663  
reactive, 664-665  
in relapsing polychondritis, 192  
rheumatoid, *see* Rheumatoid arthritis  
rheumatoid factor negative, 814  
septic, *see* Septic arthritis  
streptococcal cell wall induced, 260-264  
of subacute bacterial endocarditis, 813-814

Arthritis Coordinating Committee, 29

Arthritis Data Bank, 29

Arthritis Foundation, 29-31, 56, 655

Arthritis Plan, 29

Arthritis Programs, directors of, 33

Arthrocentesis, of knee, 234

Arthropathy, trapezioscapoid, 833

Articular cartilage  
ATPase activity in, 1337  
collagen biosynthesis in, 793  
erosion of, 769-772  
intraarticular carrageenin and, 769-775  
irreversible joint destruction and, 68  
metabolic changes due to inflammation in, 199-207  
metabolism of, 828  
proteoglycan depletion from, 68  
proteoglycan synthesis in, 918-921

Articular tissues, CPPD deposition in, 93-97

AS, *see* Ankylosing spondylitis

Ascites, in SLE, 782-785

L-Asparaginase, in lupus nephritis, 810

Aspirin  
benzbromarone and, 188-189  
BUN level and, 157-160  
glomerular filtration rate and, 159  
liver function and, 155-160  
Naproxen and, in RA combination therapy, 677-681  
in RA, 155-160  
in SLE, 155-160  
tolmetin and, in JRA, 807

Atherosclerosis, hemarthrosis and, 98

ATPase, *see* Adenosine triphosphatase

Autoantibodies  
in Sjögren's syndrome, 216-222  
in SLE, 88-90

Autoimmune nephritis, in NZB/W mice, 43

Autoimmunity, suppression of in NZB mice, 1345-1347

Autologous system, mixed leukocyte reaction in, 535

Azaribine  
categories of clinical response to, 24  
clinical response to by category of improvement, 23  
clinically active joints and, 23  
in dermatitis, 21, 27  
dosage for, 22, 27-28  
efficacy measurement for, 23  
gastrointestinal complaints from, 27  
liver and, 27  
mechanism of, 27  
number of pills needed for, 28  
orotidylate decarboxylase inhibition by, 21  
in pregnancy, 28  
in psoriatic arthritis, 21-28  
response spectrum for, 24-25  
side effects of, 23-24, 27-28  
sperm count and, 28  
toxicity of, 25-27

Azathioprine  
autoimmune nephritis and, 43  
cyclophosphamide and, 54, 693-698  
in early RA, 795  
in lupus glomerulonephritis, 819  
in NZB/W nephritis, 46, 48  
prednisone and cyclophosphamide in, 693-698  
in psoriatic arthritis, 28  
vaccinia and, 270

6-Azauridine 5'-monophosphate, 21  
*see also* Azaribine

6-Azauridine triacetate, 21, 27

## B

Bacitracin, articular cartilage and, 828

Bacterial endocarditis  
rheumatoid factor and, 887-890  
*Staphylococcus aureus* and, 887

BAL, *see* British Anti-Lewisite

B-cell dyscrasias, 173

B cells, *see* B lymphocytes

Behcet's syndrome, 32  
HLA antigens and, 659

Bella Coola Indians, ankylosing spondylitis in, 1329

Bence-Jones protein, 756  
amyloidosis and, 173, 180  
anti- $\kappa$  antisera and, 756  
degrading of, 758

Benign essential hypertension, neoplasia and, 1257

Benign monoclonal gammopathy, 175

Benzbromarone  
aspirin and, 188  
clinical evaluation of, 183-189  
defined, 183

dosage of, 175-187  
hyperuricosuria and, 184  
purine biosynthesis of, 189  
Biofeedback, in Raynaud's phenomenon, 795  
Blast cells, in rheumatoid synovitis transitional areas, 5-8  
Blastogenic responses, calculation of, 510  
Blood L lymphocytes, in SLE, RA, and scleroderma, 802-803  
Blood urea nitrogen level, aspirin and, 157-160  
B lymphocytes  
in amyloidosis, 175-176  
in familial Mediterranean fever, 618  
macrophages and, 8-10  
in rheumatoid synovitis, 8-10  
BMG, *see* Benign monoclonal gammopathy  
Bovine cartilage, proteoglycan fractions for, 1310  
Bovine knee cartilage, normal vs osteoarthritic, 211  
Bovine serum albumin, thermal denaturation of, 595  
Brain scan, in SLE, 826  
British Anti-Lewisite, in gold overdose, 123-124  
5-Bromodeoxyuridine, in lymphocyte measurement, 720-723  
Bronchogenic carcinoma, 629-635  
BUDR, *see* 5-Bromodeoxyuridine  
BUN, *see* Blood urea nitrogen  
Bunim Memorial Lecture, 655-665  
Butazolidin, in ankylosing spondylitis, 111

## C

C2 complement dependency, 517-522, 798  
skin lesions in, 521  
C3 complement, activation of by sera and synovial fluids, 803  
Calcium pyrophosphate dihydrate crystals, 93-97, 967  
arthritis and, 823  
corticosteroids and, 1369-1370  
removal of, 96  
solubility of, 94, 96  
*Candida*, in SLE, 89-90  
Canine hemoarthrosis, 59-66  
*see also* Hemoarthrosis  
Caplan's syndrome, 32  
Carcinoma, bronchogenic, *see* Bronchogenic carcinoma  
Carcinomatous polyarthritides, 953-957  
radioisotope uptake in, 955  
Carpal arthritis, 232-241  
Carpal tunnel, *Mycobacterium intracellulare* infection and, 777-780  
Carpo/metacarpal ratio, in rheumatoid arthritis, 939-944  
Carrageenin  
inflammatory response to, 775  
intraarticular injection of, 771  
lysosomal enzyme stimulation of, 1291-1292  
multiple injection of, 773  
phagocytic cell uptake of, 775  
Carrageenin-induced arthritis, 769-775, 918-921, 1287-1293  
Cartilage  
articular, *see* Articular cartilage  
biosynthesis of matrix components of, 202  
cathepsin D and, 1296  
deformation in hemarthrosis, 63  
hexosamine in, 62  
mechanical properties of, 209  
proteoglycan contents of, 771  
transplantation of, 223  
Cartilage antigens, humoral response to, 223  
Cartilage destruction, collagen loss and, 68-69  
Cartilage proteoglycans  
aggregation of, 1308-1314  
degradation by superoxide radical, 799  
enhancement of collagenase activity by, 799  
Cathepsin B1, in cartilage degradation, 1293  
Cathepsin D  
autoradiographic studies and, 1303-1304

detection of in extracellular locations, 1298-1303  
lysosomal enzyme activity and, 1291-1292  
operating theater cultures and, 1303  
in osteoarthritic cartilage, 205  
preparation of, 1288  
rat chondrocyte antigens and, 230  
secretion and localization of in synovial tissues, 1295-1305  
synovial, 738, 1295-1305  
Cell-associated antigen, in RA, 711-718  
Cell-mediated immunity, decrease of, 1274-1275  
Cellular hypersensitivity, in RA and in ankylosing spondylitis, 539-543  
Cellular immune abnormalities, in amyloidosis, 173-180  
CEMPAF, *see* Committee for the Evaluation of the Medical Programs of the Arthritis Foundation  
Cerebral radionuclide angiogram, in SLE, 826  
CFANA, *see* Complement fixing antinuclear antibody  
CH50 (total hemolytic component), in JRA, 161-166  
Chapter Medical Program Subcommittee, 33  
Charnley total hip prosthesis, 691  
Chemotaxis, polymorphonuclear leukocyte, 825-826  
Childhood arthritis, 820, 824  
B27 positive patients in, 820  
hypertrophic osteoarthropathy in, 902-906  
onset of, 820  
pauciarticular, 820-821  
Childhood polyarthritis, 662  
Chloroquine  
in ankylosing spondylitis, 113-114  
in RA, 113-114  
Chondrocalcinosis, 94-95, 833  
Chondrocyte, rat, *see* Rat chondrocyte  
Chondromalacia patellae, 637-638  
Chondromucoprotein, erosion of, 230  
Chondroitin sulfate, 209, 212-214, 771, 1308  
Chryotherapy, 1321-1327  
*see also* Gold salts  
CIE, *see* Counterimmunoelectrophoresis  
"Cigarette paper" scar, 763-766  
Cigarette smoking, lung damage from, 627  
Circulating immunoglobulins, in NZB/W nephritis, 46  
*see also* Immunoglobulins  
<sup>14</sup>C-labeled *Staphylococcus aureus*, 618-619  
Clayton operation, for feet, 31  
Clinical Investigations Study Group on Rheumatic Diseases, 655  
Clubbing  
in childhood arthritis, 903-906  
hypertrophic osteoarthropathy and, 643-644  
Coagulation, intravascular, *see* Intravascular coagulation  
Coagulation abnormalities, in rheumatoid disease, 1235-1239  
Coal miners  
pneumoconiosis in, 731-735  
RA in, 731-735  
serum immunoglobulin levels in, 734-735  
Colchicine  
dosage in, 620-621  
in rheumatoid synovium, 69  
Colchicine therapy  
in familial Mediterranean fever, 618-621  
skin-window test in, 620  
Colitis, ulcerative, 660  
Collagen  
degradation of by superoxide radical, 799  
incidence of antibodies to, 615  
incubation of with collagenases in erythrocyte coupling, 614  
loss of in cartilage destruction, 68-69  
synthesis of by cartilage explants in vitro, 200  
Collagenase, in human leukocytes, 829  
Collagenase activity  
enhancement of, 799  
inflammation and, 203  
Collagen biosynthesis, by human articular cartilage, 793

Collagen chains, incidence of antibodies to, 615  
Collagen production, lymphocyte factor stimulation of, 794  
Collagen synthesis  
  fibroblasts in, 861  
  net protein and, 895-897  
  <sup>14</sup>C-proline incorporation in, 894  
Committee for Evaluation of Medical Programs of the Arthritis Foundation, 34-35  
Complement system, intraarticular activation of, in JRA, 161-166  
Comprehensive Arthritis Centers, 29  
Computer Committee, ARA, 645-647  
Concanavallin A (con A), 509  
  in amyloidosis, 173, 179  
  in RA, 720-724  
Concanavallin response, lymphocyte response to, 512, 875  
Connective tissue activating peptide  
  in collagenase/protease production and release, 70  
  psoriasis and, 611  
Connective tissue diseases, RA precipitin in, 713-714  
Connective tissue synthesis, by cultured scleroderma fibroblasts, 891-900  
Consultant rheumatologists, geographic distribution of in U.S., 56-58  
Contraceptives, oral, and rheumatoid factor, 604  
Convertase, in JRA, 161  
Coombs' antibody, in NZB mice, 1354  
Coombs' test, on NZB mice, 1348-1349, 1356  
Copper, concentration of in rheumatoid patients, 597-598  
Corticosteroid therapy  
  CPPD crystals and, 1369-1370  
  in NZB/W nephritis, 54  
  organic brain syndrome and, 1333-1337  
  in SLE, 79-81, 195-197  
*Corynebacteriaceae*, 41  
*Corynebacterium rubrum*, 41, 258  
Coumadin therapy, in Hemarthrosis, 98-101  
Counterimmunolectrophoresis, 574-579  
  complement activation and, 787  
  vs hemagglutination, 579  
  identification of precipitins by, 578  
  mechanism of, 575-576  
  in Sjögren's syndrome, 578  
CPPD crystals, *see* Calcium pyrophosphate dihydrate crystals  
Creatine phosphokinase, in hypothyroidism, 1364-1365  
CREST syndrome, 32  
Critical electrolyte concentration reactions, cRNA, in *Erysipellothrix* arthritis, 39  
Crohn's disease, 660  
  HLA antigens and, 662-663  
Cryoglobulinemia, in Felty's syndrome, 103-109  
Cryoglobulins, in Felty's syndrome, 106  
Cryoprecipitates, lymphocytotoxic antibody activity in, 844-849  
Cryoproteins, alternative complement pathway in, 829  
Crystal shedding  
  in acute pseudogout, 93-97  
  calcium crystals in, 96  
  defined, 93-94  
  solubility studies in, 94  
CTAP, *see* Connective tissue activating peptide  
Cutaneous necrotizing venulitis, HLA genes and, 945-949  
  *see also* Angiitis  
Cutaneous vessel immune deposits  
  antinuclear antibodies and, 16  
  biopsy specimens in, 16  
  fluorescein-conjugated antisera in, 16  
  frequency of, 16  
  laboratory tests in, 16  
  patient selection in, 16  
  in RA, 15-19  
Cyclic AMP  
  interferon and, 1319

SLE serums and, 77  
Cyclophosphamide  
  adverse effects of, 569  
  in autoimmune nephritis, 43  
  azathioprine and, 54  
  circulating DNA antibodies and, 52  
  delayed immune response and, 570-571  
  disease activity and, 565-567  
  dosage of, 53, 565  
  in lupus glomerulonephritis, 819  
  in lupus nephritis, 693-698  
  in NZB/W nephritis, 46, 49-54  
  onset and duration of drug effect in, 567-568  
  primary humoral immune response and, 570  
  in RA, 563-572  
  serum immunoglobulins in, 570  
  X-ray changes and, 568-569  
Cystine, concentration of in rheumatoid patients, 597-599

## D

dAT, *see* Polydeoxyribonucleotide  
Degenerative arthritis, 65  
Degenerative joint disease  
  smoking and, 624  
  synovitis in, 813  
Dermatitis, azaribine and, 21, 27  
Dermatitis herpetiformis, HLA-B8 and, 883  
Dermatoglyphics, 83-86  
Dermatomyositis  
  capillary microscopy in, 1370  
  counterimmunolectrophoresis in, 578  
Dibutyryl adenosine cyclic 3':5'-monophosphate, 69  
Diffuse interstitial fibrosis (DIF), 639  
Digital arteritis, of hand, 19  
2,4-dinitrochlorobenzene  
  immune response to, 563  
  in RA delayed immune response, 564-565  
Discoid lupus erythematosus, 517-522  
  *see also* Systemic lupus erythematosus  
Disodium EDTA, in CPPD crystal solubility, 94  
  *see also* EDTA  
DJD, *see* Degenerative joint disease  
DNA (deoxyribonucleic acid)  
  double stranded, 810  
  nephritis and, 49  
DNA antibodies, in NZB/W nephritis, 50-53  
DNA antibody, cryoglobulins and, 848  
DNA-anti-DNA coated cells, in SLE, 797  
DNA-anti-DNA complexes, in NZB/W nephritis, 49  
DNA binding, in ds/ss heterogeneity, 810  
DNA (dsDNA), antibodies to, 963-964  
DNA synthesis, in amyloidosis, 179  
DNA tolerance, in NZB/W mice, 826  
DNCB, *see* 2,4-dinitrochlorobenzene  
Dogs  
  experimental hemarthrosis of knee in, 59-66  
  RA in, 970-971  
Down's syndrome, psoriatic arthritis and, 651  
Drug abuse, rheumatic complication in, 923-926  
Dysproteinemia, Sjögren's syndrome and, 1336

## E

EBNA, *see* EBV-determined nuclear antigen  
EBV, *see* Epstein-Barr virus  
EBV-determined nuclear antigen, 717  
Echo viruses, arthritis and, 1317  
EDTA (ethylenediaminetetraacetate), in CPPD crystal solubility, 94

chelating abilities of, 96  
gamma globulin viscosity increment and, 596  
Ehlers-Danlos syndrome, 763-764, 767-768  
EI, *see Erysipelothrrix insidiosa*  
Electron microscope studies  
of immunoreactive cells in rheumatoid synovial membrane, 1-13  
of perivascular accumulations, 3-5  
of rheumatoid synovial membrane, 1-13  
Emphysema, anticollagen antibodies in, 616  
ENA, *see Extractable nuclear antigens*  
Endocarditis  
bacterial, *see Bacterial endocarditis*  
subacute, 813-814, 889  
Enzyme release, *see Lysosomal enzymes*, release of  
Enzymes, collagenolytic system and, 69  
Eosinophilia  
fasciitis and, 792  
morphea and, 792  
scleroderma and, 792  
Epidermal epithelial cells, in PSS, 969-970  
Epon 812, 2  
Epstein-Barr virus, 717  
Erosive synovitis  
adjuvant arthritis and, 257-259  
*Erysipelothrrix insidiosa* arthritis and, 256-257  
mechanistic model of, 262-264  
pathogenic model for, 256-264  
streptococcal cell wall induced arthritis and, 260-261  
*Erysipelothrrix* arthritis, 38, 262  
DNA preparations in, 40  
hybridization studies in, 40  
immunohistology in, 40  
nuclear acid hybridization in detection of, 38-42  
*Erysipelothrrix insidiosa*, 38, 256-257  
arthritis caused by, 256-257  
*Erysipelothrrix* synovitis, 262  
Erythrocyte sedimentation rate  
cyclophosphamide and, 566-567  
in relapsing polychondritis, 191  
*Escherichia coli*, arthritis and, 169, 171  
Esophageal varices, in Felty's syndrome, 150-152  
Essential hypertension, benign, 1259  
Extracellular cathepsin D, detection of, 1304-1305  
*see also* Cathepsin D  
Extractable nuclear antigens, antibodies to, 851-856

## F

Factor II deficit, in SLE, 81  
Familial Mediterranean fever  
cutaneous inflammatory responses in, 619-620  
lymphocyte studies in, 614  
Fasciitis, eosinophilia and, 792  
FDP, *see Fibrinogen degradation products*  
Felty's syndrome  
antinuclear antibody studies in, 104-106, 108  
case report in, 150-151  
circulatory immune complexes in, 108  
clinical characteristics of, 105  
cryoglobulins in, 104-107  
cryoimmunoglobulinemia in, 103-109  
esophageal varices in, 150-154  
kidney reactive antinuclear factor in, 109  
laboratory characteristics of, 105-106  
patient population in, 104  
SGOT level in, 153  
splenectomy in, 150, 153  
white cell abnormalities in, 108  
Fenoprofen calcium, in gouty arthritis, 933-935  
Fibrin, in skin immunoreactants, 17  
Fibrinogen catabolism, in SLE, 195-198

Fibrinogen degradation products, 196-197  
Fibrinogen metabolism, 198  
Fibrinolysis, *see Intravascular coagulation and fibrinolysis*  
Fibrin split products, in serum, 1239  
Fibroblast degeneration, in rheumatoid synovitis, 6, 10  
Fibroblasts  
in collagen synthesis, 816  
in scleroderma, 816-817  
Fibrous myopathy, 923-926  
Ficoll-Hypaque separated lymphocytes, in SLE, 89  
Filtered *E. coli* DNA, 868  
*see also* *Escherichia coli*  
Fine structure analysis techniques, 581-591  
Fingers, clubbing of, 903-906  
Fischer rat chondrocytes, *see Rat chondrocytes*  
Floppy thumb sign, 243-244  
Fluorescein-conjugated antisera, 16  
Fluorescent band skin test, 792  
FMF, *see* Familial Mediterranean fever  
Freund's adjuvant, 259  
*see also* Adjuvant arthritis  
FSP, *see* Fibrin split products  
Functional test, in RA, 1278, 1281-1285

## G

GAG, *see* Glycosaminoglycans  
Gamma globulin  
denaturation of, 593-599  
human, *see* Human gamma globulin  
inhibition of, 593-599  
Gastrointestinal tract hemorrhage, in Felty's syndrome, 150-152  
*Genu amoris*, case report in, 637-638  
Glomerular filtration rate, aspirin and, 159-160  
Glomerulonephritis, 195  
Glycol methacrylate  
in adjuvant arthritis, 1340  
kidney sections embedded in, 1344  
Glycoprotein, in amyloidosis, 173  
Glycosaminoglycans, of normal and OA cartilage, 209  
Glycosaminoglycan synthesis  
in hemarthrosis, 63-65  
hexosamine and, 65  
Gold and gold salts  
*see also* Chrysotherapy  
in ankylosing spondylitis, 113  
British Anti-Lewisite in overdose of, 124  
effectiveness of, 1323-1326  
failures of, 1326  
in kidney, liver, and spleen, 1368-1369  
overdoses in ventricular tachycardia, 1373-1374  
in RA, 598, 796, 927, 1321  
radioactive, *see* Radiogold  
secretion of in mother's milk, 1374  
side effects of, 1321-1322  
Gold sodium thiomalate, 927, 1322-1328  
inhibition of lymphocytes by, 808  
synthesis of, 928  
Gold toxicity, peritoneal dialysis and, 936-938  
Gonococcal arthritis, low-dose penicillin therapy in, 826-827  
Gout  
hypothyroidism in, 123  
renal tubular defect in, 828-829  
tubular transport of urate in, 811  
Gouty arthritis  
fenoprofen calcium in, 933-935  
indomethacin/aspirin in, 933  
Gouty tophi, localization of immunoglobulin in, 802  
Graves' disease, HLA-B8 and, 883  
Group A streptococci, in Sydenham's chorea, 803  
Guanidinium, proteoglycans and, 210-212

## H

Haida Indians, ankylosing spondylitis in, 1331-1332

**Hand**  
deforming arthritis of, in polymyositis, 243-248  
digital arteritis in, 19  
immunoglobulins of, 19  
in Still's disease, 235-240

Hanks' balanced salt solution, 174

Heberden's nodes, pre-Columbian representation of, 125-126

Hemagglutination enhancement test, in RA, 612-615

Hemagglutination inhibition test, in RA, 614

**Hemarthrosis**  
anticoagulant therapy in, 99  
atherosclerosis and, 98  
biochemical results in, 62  
biomechanical tests in, 60-63  
in canine knee joints, 59-66  
cartilage deformation in, 63-64  
case reports in, 98-100  
experimental, 59-66  
flexion deformities in, 60  
GAG content in, 64  
hemophilia and, 59  
heparin therapy in, 966  
hyperlipidemia and, 98  
as monarthritis, 101  
morphology of, 60-62  
plasmacytomas and, 99  
sodium warfarin therapy in, 98-101  
vitamin K therapy in, 101

**Hemochromatosis**, 32

**Hemophilia**, hemarthrosis and, 59

**Henoch-Schönlein purpura**, IgA deposition in, 831

**Henoch-Schönlein syndrome**, 949

**Herapin therapy**, hemarthrosis secondary to, 966

**Hepatic injury**, salicylate-induced, 964-965

**Hepatitis**  
drug abuse and, 923  
HLA-B8 antigen and, 803

**Hepatitis B**, research in, 31

**Hereditary homozygous C2 deficiency**, 517-522

**Herpes virus**, lymphocyte response to, 1269

**Hexosamine**, GAG synthesis and, 65

**Hip abnormalities**, radiologic findings in, 685

**Hip involvement**, in ankylosing spondylitis, 683-692

**Hip surgery**, bony reankylosis in, 691-692

**Histidine**  
inhibitory effect of, 599  
viscosity increment and, 595

**Histidine concentration**, in RA, 593

**Histidine-cystine-copper mixtures**, in gamma globulin denaturation inhibition, 593-599

**Histiocytic lymphoma**, 252

**Histochemical investigation**, of adjuvant-induced arthritis, 1339-1345

**Histocompatibility antigens**, 656-657  
*see also HLA antigens*  
in SLE, 129-131

**Histocompatibility complex**, 657-658

**HLA antigens**  
*see also Histocompatibility antigens*  
in acute anterior uveitis, 660  
in ankylosing spondylitis, 659-660  
Behget's disease and, 659  
cutaneous necrotizing venulitis and, 945-949  
disease concept and, 661-662  
first international symposium on, 37  
mixed leukocyte reactions and, 532  
nonrheumatic diseases and, 658  
other genetic factors and, 659-660  
pairs of, 946  
peripheral arthritis and, 660-661

psoriasis and, 611  
Reiter's disease and, 664  
research in, 31  
rheumatoid arthritis and, 537  
in SLE, 129-131, 658  
in sternomanubrial joint disease, 1372

**HLA-A antigen**, 657

**HLA-All antigen**, 947

**HLA-B antigen**, 657

**HLA-B8 antigen**  
diseases associated with, 883-885  
in Sjögren's syndrome, 811, 882-886

**HLA-B27 antigen**, 656-665  
in ankylosing spondylitis, 804-805, 1326  
in Pima Indians, 791  
in seronegative arthritis, 795-796

**HLA-BW35 antigen**, 947

**HLA-C antigen**, 657, 659

**HLA-D antigen**, 657, 659, 661  
in progressive systemic sclerosis, 749

**HLA-haplotype 10, W18 antigen**, 517-522

**HOA**, *see* **Hypertrophic osteoarthropathy**

**HPO**, *see* **Hypertrophic pulmonary osteoarthropathy**

**Human gamma globulin**  
denaturation of, 593  
histidine-cystine-copper mixtures and, 593-599  
viscosity increment of, 595-596

**Human lymphocytes**, *see* **Lymphocytes**

**Human synovial cells**, hyaluronic acid production and, 1315-1318

**Human synovial fluid**, mononuclear cells in, 743-748

**Humoral antibody response**, in RA, 564  
*see also* **Antibodies**

**Humoral immune abnormalities**, in amyloidosis, 173-180

**Hyaluronic acid**  
from human synovial fibroblasts, 1315-1319  
interferon and, 1317-1319  
overproduction of, 1316  
rabbit synovial cells and, 70, 587-588

**Hydroxychloroquine sulfate**, lymphocytes and, 910

**<sup>14</sup>C-Hydroxyproline**, in scleroderma fibroblasts, 893

**Hyperextensible joints**, in Marfanoid hypermobility syndrome, 764-765

**Hypergammaglobulinemia purpura**, 949

**Hyperlipidemia**, hemarthrosis and, 98

**Hyperostosis**, ankylosing, of spine, 818

**Hypersensitivity angiitis**, 949

**Hypertension**, tubular transport of urate in, 811

**Hypertrophic pulmonary osteoarthropathy**  
in bronchogenic carcinoma, 629-635  
clubbing and, 643-644  
RA and, 639  
secondary, 902-906  
synovial effusions in, 633-634

**Hyperuricosuria**, benzboromarone and, 185

**Hypocomplementemia**, 837  
fibrinogen consumption and, 195  
in HLA antigens, 947

**Hypothyroidism**  
gout and, 123  
muscular weakness and, 1365  
as polymyositis-like syndrome, 1363-1366

in skin immunoreactants, 17  
as primary homocytotropic antibody, 671  
in SLE, 671-672  
IgG antibody  
in LDAC studies, 146-148  
in normal skin vessels, 18  
opsonic activity reduction in, 77  
rheumatoid factor and, 827  
in skin immunoreactants, 17  
IgG antilymphocyte antibodies, in SLE, 1261-1268  
IgG galactose deficiency, in RA and SLE, 813  
IgM antibody, in normal skin vessels, 18  
IgM rheumatoid factor, 661  
IgM-to-IgG switching, 819  
Immune deposits, in cutaneous vessels, *see* Cutaneous vessel immune deposits  
Immune synovitis, osmotic acid in, 737-742  
Immunofluorescence microscopy, in RA, 557  
Immunofluorescence test, in rat chondrocyte antigen profile, 225-227  
Immunoglobulin light chain, in primary amyloidosis, 755-758  
Immunoglobulins  
deposit of in cutaneous vessels, 15-19  
glomerular deposition of, 1356  
in SLE, 670-671  
Immunoreactive cells in rheumatoid synovial membrane, 1-13  
Indirect hemagglutination test, 649  
Indomethacin, 907  
aspirin and, 933  
lymphocytes and, 910, 915  
in pseudogout, 95  
Inflammation  
lysosomal enzymes in, 73, 203-206  
phagocytic cells in, 73  
in RA, 68  
in rabbit articular cartilage metabolism changes, 199-207  
Inflammatory arthritis, hip involvement in, 689  
Inflammatory myopathy, myoglobinemia in, 804  
Inflammatory process, *see* Inflammation  
Interferon  
cyclic AMP and, 1317  
in rheumatoid synovial fluids, 1317-1319  
Intervertebral disk degeneration, 817  
Intravascular coagulation and fibrinolysis  
overcompensated, 1240-1241  
in RA, 1237-1241  
Intravascular drug abuse, fibrous myopathy  
and, 923-926

## J

Joint destruction, irreversible, 68  
Joint dislocation, in neuropathic arthropathy, 1365-1366  
Joint lavage, in chondrocalcinosis of knees, 93-94  
Joint replacement, synovial debris following, 793  
Joseph J. Bumim Memorial Lecture, 655-665  
JRA, *see* Juvenile rheumatoid arthritis  
Juvenile rheumatoid arthritis  
amyloid protein SAA in, 789  
ankylosis and, 240  
cataracts in, 788  
complement system intraarticular activation in, 161-166  
hip joint restoration in, 789-790  
pericardial tamponade in, 760-762  
serum complement values in, 164-165  
serum glutamate oxaloacetic transaminase in, 115-118  
serum glutamic pyruvic transaminase in, 115-118  
serum immunoglobulin levels in, 165-166  
SLE and, 115-118  
synovial fluid values in, 162-163  
tolmetin and aspirin in, 807  
transaminase and serum salicylate concentrations in, 115-118

## K

Keitel functional test, 1278-1285  
Keratan sulfate, 209  
Ketoprofen, in RA, 791  
Kidney, gold levels in, 1368-1369  
Killer cell  
character of, 135  
in LDAC system, 133-134, 138-139  
Kininogen, in JRA, 161-166  
Knee  
arthritis of, 637-638  
arthrocentesis of, 234  
cathepsin D localization in, 1295-1305  
chondrocalcinosis of, 93  
*Mycobacterium intracellulare* infection of, 777-780  
osteoarthritic cartilage of, 209-214  
Knee joints  
hemarthrosis of, 98-101  
rabbit, *see* Rabbit knee joint  
torn medial meniscus and, 99  
Kupffer cells, gold distribution in, 927-928

## L

Lactate formation, in synovial cells, 70  
Lactic dehydrogenase, in hypothyroidism, 1365  
Lactoferrin-to-lysosome ratio, in synovial fluid, 789  
Lansbury articular index, 1278  
Large mononuclear cells, in synovial fluid, 743-748  
Latex, in proliferative lesions, 69  
LBT, *see* Lupus band test  
LDAC, *see* Lymphocyte-dependent antibody cytotoxicity  
LE cells, in lungs, 249-252  
*see also* Systemic lupus erythematosus  
Leech hyaluronidase, proteoglycan digestion by, 1309  
Leg ulcers, in RA, 18  
Leukemia-lymphoma, amyloidosis and, 174-177  
Leukocyte reaction, mixed, *see* Mixed leukocyte reaction  
Leukocyte migration inhibition test, 540, 543  
Leukocyte pyrogen production, colchicine and, 619  
Leukocyte response, to synovial RA extracts, 798  
*see also* Mixed leukocyte reaction  
Leukocytes  
latent collagenase activation in, 829  
lysosomal enzyme release in, 74  
Leukocytic protein, production of, 618  
Linear variable displacement transducer, 60-61  
*Listena monocytogenes*, 38  
Lithium heparin crystals, in CPPD crystals, 966-967  
Liver, gold levels in, 928, 1368-1369  
Liver enzymes, salicylates for, 267-268  
Liver function, aspirin and, 155-160  
LKB microtome, 2  
LL, *see* Leukemia-lymphoma  
LMN, *see* Large mononuclear cells  
Lungs  
in RA, 732  
in SLE, 249-252  
Lupus anticoagulant, 1244-1246  
antibody nature of, 1246  
Lupus band test, 1249-1254  
Lupus erythematosus  
*see also* Systemic lupus erythematosus  
amyloidosis and, 249-252  
discoid, *see* Discoid lupus erythematosus  
lymphoproliferative disease and, 251  
in pleural fluid, 962-963  
Lupus glomerulonephritis  
cyclophosphamide and azathioprine in, 819  
defined, 833

Lupus nephritis  
*see also* SLE  
 L-asparaginase treatment of, 810  
 complement-fixing antinuclear antibodies in, 857-860  
 double-blind crossover trial in, 695  
 prednisone-azathioprine-cyclophosphamide in treatment of, 693-698

LVDT, *see* Linear variable displacement transducer

Lymph nodes, immunologic stimulation of, 252

Lymphoblasts  
 in rheumatoid synovitis, 7  
 in synovial fluid, 745-747

Lymphocyte activity, in RA, 509-515

Lymphocyte-dependent antibody cytotoxicity, 133-140  
 B-cell subpopulation in, 138  
 gel filtration experiments in, 143-145  
 inhibition of, 135-136, 138-140  
 killer cell in, 133, 135, 138-139  
 measurement of, 134  
 in patients with RA and SLE, 136-138  
 preincubation experiments in, 145-147  
 serum inhibitors of, 142-149  
 synovial fluid inhibitors of, 142-149  
 stimulation of collagen production and, 794

Lymphocyte fractionation, in LDAC testing, 134

Lymphocyte populations, in RA, 720-724

Lymphocyte responsiveness  
 in ankylosing spondylitis, 798  
 modification of by complement, 806  
 in progressive systemic sclerosis, 875-881  
 in scleroderma, 805  
 in SLE, 88-91

Lymphocytes  
 antirheumatic drugs and, 907-916  
 "effector" roles of, 258  
 infiltration of rheumatoid synovium by, 1  
 inhibition of by gold sodium thiomalate, 808  
 in vitro immunoglobulin synthesis of, 830  
 mitogen-stimulated, 744, 1265-1267  
 peripheral blood, *see* Peripheral blood lymphocytes  
 in perivascular accumulations, 6-8  
 in RA, 523  
 Type C virus related antigens and, 809  
 viability of, 911

Lymphocyte transformation, in amyloidosis, 176

Lymphocytic antibodies, in SLE patients and relatives, 700-703

Lymphocytic choriomeningitis, 657

Lymphocytotoxic antibodies  
 in cryoprecipitates from SLE patients, 844-849  
 in SLE, 546-549, 817-818

Lymphocytotoxicity  
*see also* Lymphocyte-dependent antibody cytotoxicity  
 antibody-mediated, 133-140  
 in RA, 133-140  
 in SLE, 133-140  
 suppression of in SLE, 831

Lymphokine(s), in RA, 70

Lymphokine-like substances, in synovial fluid, 10

Lymphokine production, in SLE, 794

Lysosomal enzymes  
 inflammation and, 203-206  
 PMN and, 74-75  
 reduction of in SLE, 73-77  
 stimulation of, by carrageenin, 1291-1292

Lysosomes, gold distribution in, 928

**M**

Macrophage phagocytosis, serum and granuloma protein inhibitors of, 790

Macrophages, in rheumatoid synovitis, 8-10

MAK chromatography, 867

Mandible  
 bone erosion of, in scleroderma, 1369  
 resorption of, in vinyl chloride acro-osteolysis, 971

Marfan syndrome, 763, 766-768

Marfanoid hypermobility syndrome, cardiovascular abnormalities in, 763-768

Maternal milk, gold secretion in, 1374

Maximal midexpiratory flow rates, in pulmonary disease, 624-626

MCTD, *see* Mixed connective tissue disease

Measles, lymphocyte response to, 1271

Medical Administrative Committee, Arthritis Foundation, 29-30

Mediterranean fever, familial, 618-621

Membrane receptor studies, of rabbit synovial cells, 587-588

Meperidine, abuse of, 923

6-Mercaptopurine, in psoriasis, 28

Metabolic inhibition technique, 1326-1330

Metacarpophalangeal joints, ankylosing spondylitis of, 111-112

Metatarsophalangeal joints, ankylosing spondylitis of, 111

d-2-(6'-methoxy-2'-naphthyl)propionic acid, *see* Naproxen

Methylated albumin-Kieselguhr chromatography, 867

Methylprednisolone, in NZB/W nephritis, 46

Mice, NZB/W, *see* NZB/W mice

$\beta$ 2-Microglobulin, SLE and, 968

Midline granuloma, nasal septum perforation in, 119

MIF (melanocyte-stimulating hormone inhibitory factor), in synovial fluid, 10-13

MIT, *see* Metabolic inhibition technique

Mitogen responses, in SLE twin studies, 548-550

Mitogens  
*see also* Concanavallin A; Phytohemagglutinin P  
 lymphocyte responsiveness to, 509-514  
 in progressive systemic sclerosis, 875-881

Mitogen stimulation  
 lymphocytes and, 1265-1267  
 in SLE, 827-828

Mixed connective tissue disease, 32  
 antibodies to nuclear antigens in, 574  
 in children, 788, 822  
 complement-fixing antinuclear antibody in, 857-860  
 extractable nuclear antigens and, 851-856  
 nasal septum perforation in, 119-121  
 precipitin identification in, 578  
 pulmonary involvement in, 801  
 ribonucleoprotein and, 851

Mixed cryoglobulinemia, nasal septum perforation in, 119-121

Mixed leukocyte cultures, in SLE twin studies, 546, 549

Mixed leukocyte reaction  
 in autologous serum, 535  
 in RA, 532-537  
 salicylate effect in, 536

Mixed lymphocyte culture  
 in HLA typing, 657, 659  
 3HTdR uptake and, 911-912

MLC, *see* Mixed leukocyte culture; Mixed lymphocyte culture

MLR, *see* Mixed leukocyte reaction

MM, *see* Multiple myeloma

Mnemonics, use of, 650-651

Monarthritis, hemarthrosis as, 101

Monoclonal immunoglobulins, in amyloidosis, 173

Monocytes, in synovial fluid, 745-747

Mononuclear cells  
 in human synovial fluid, 743-748  
 large, 743-748  
 normal, 745  
 in SLE, 89

Monosodium urate crystals  
 immunoglobulin and, 802  
 protein adsorption to, 805

Morning stiffness, 1283  
Morphea, eosinophilia and, 792  
MSU, *see* Monosodium urate  
Multiple myeloma, amyloidosis and, 174-177  
Multiple sclerosis, hereditary C2 deficiency in, 521  
Mumps, arthritis and, 1317  
Murine amyloid, protein AA and SAA in, 822-823  
Murine NZB/W disease, *see* NZB/W nephritis  
Myasthenia gravis, HLA-B8 and, 883  
*Mycobacterium avium*, 777  
*Mycobacterium bovis*, 777  
*Mycobacterium intracellulare*, chronic arthritis due to, 777-780  
*Mycobacterium kansasii*, 779  
*Mycobacterium leprae*, 777  
*Mycobacterium tuberculosis*, 777  
*Mycoplasma hyorhinus*, 41  
*Mycoplasma spp.*, 649-650  
Myochrysine, 927  
Myoglobinemia, in inflammatory myopathy, 804  
Myopathy, inflammatory, 804  
Myositis ossificans, 925  
Myxedema heart disease, 1365

## N

Nailfold capillary microscopy, 1370  
Naprosyn, 677  
Naproxen, 907  
Naproxen-aspirin combination therapy  
  efficacy, evaluation of, 678-680  
  premature discontinuation of, 678  
  in RA, 677-681  
  tolerance to, 680  
Nasal septum perforation, in rheumatic diseases, 119-121  
National Advisory Committee on the Future of Arthritis Research, 31-32  
National Arthritis Act of 1975, 29, 645  
National Commission on Arthritis, 29  
National Institute of Arthritis and Metabolic Diseases, 655-656  
National Institutes of Health, 30-31, 655  
Neoplasia, in RA and SLE, 1256-1260  
Nephritis  
  autoimmune, 43  
  lupus, 810  
Neuropathic arthropathy, joint dislocation in, 1367-1368  
Neutrophil elastase, 627  
Neutrophilic functions, pregnancy-associated serum factor in, 815-816  
Neutrophil migration  
  colchicine therapy and, 620  
  in vitro, 619  
New Zealand black/white mice, *see* NZB/W mice  
*Nocardia asteroides*, 258  
Nonimmune rabbit serum, in cathepsin D localization, 1297-1303  
Nonimmune sheep serum, in cathepsin D localization, 1297-1303  
Nonrheumatic diseases, HLA antigens in, 658  
Nuclear acid protein, antibody detection and, 574-576  
Nuclear antigens, extractable, 851-856  
Nuclear ribonucleoprotein, in Sjögren's syndrome, 576  
Nucleic acid, *see* DNA; *see also* RNA  
Nucleic acid hybridization  
  detection and semiquantitation of tissue microorganisms by, 38-42  
  materials and methods in, 38-39  
NZB/W mice  
  antinuclear antibody in, 1354-1355  
  autoimmunity suppression in, 1347-1349  
  Coombs' antibody in, 1354  
  Coombs' test in, 1348-1349, 1356

in cyclophosphamide studies, 50  
DNA-anti-DNA complexes in, 49  
DNA tolerance in, 826  
immunoglobulin classes and subepidermal deposits in, 797  
kidney tissue in, 45  
lupus nephritis in, 810  
mortality in, 1355  
polyriboadenylic binding in SLE of, 705-709  
renal histopathology in, 1315-1316  
SLE in, 693, 705-709  
therapeutic studies in, 43-48  
thymocyte-treated, 1347-1349  
transfer of spleen cells in, 1353-1357  
NZB/W nephritis, 43-48  
azathioprine in, 46  
corticosteroids in, 54  
cyclophosphamide in, 46, 49-54  
DNA antibodies in, 50-53  
methylprednisolone in, 46

## O

OA cartilage, *see* Osteoarthritic cartilage  
OAF, *see* Osteoclast activating factor  
OBS, *see* Organic brain syndrome  
Obstructive pulmonary disease, in RA, 623-627  
OC, *see* Oral contraceptives  
Oral contraceptives, side effects of, 602-606  
Organic brain syndrome  
  Sjögren's syndrome and, 1334  
  SLE and, 1336  
  treatment and response in, 1335  
Organizing Committee for Pediatric Rheumatology, 36  
Osmic acid, in immune synovitis, 737-742  
Osteoarthritic cartilage  
  cathepsin D type enzyme in, 205  
  collagen content of, 199  
  ground substance proteoglycans in, 209-214  
  other proteoglycans from, 1308-1314  
Osteoarthritis  
  fenoprofen in, 933  
  fundamental defect in, 209  
  joint destruction in, 199  
Osteoarthropathy  
  hypertrophic pulmonary, *see* Hypertrophic pulmonary osteoarthropathy  
  secondary hypertrophic, 902-906  
Osteoclast activating factor, 70  
Osteophytosis, in ankylosing spondylitis, 686-688  
Osteoporosis, polymyositis and, 244  
Ouchterlony studies, in RA, 713  
Ovarian failure, cyclophosphamide-induced, 693  
"Overlap syndrome," in polymyositis, 245-246, 248

## P

PA, *see* Primary amyloidosis  
Panmesenchymal reaction, 1335-1336  
Pannus/cartilage junction, intracellular collagen at, 801-802  
Pannus cells, primary culture of, 69  
Parainfluenza, lymphocytic response to, 1271  
Paraproteinemias, monoclonal, 959  
Parathyroidectomy, pseudogout and, 96  
Partial thromboplastin time, lupus anticoagulant and, 1244  
Patellar scraping, in hemarthrosis, 99  
Paciarticular childhood arthritis, 820-821  
PBL, *see* Peripheral blood lymphocytes  
P-component  
  amino acid analyses and, 752-753  
  in plasma, 753  
  sequencing and, 253

Pemphigus, gold compounds in, 927  
 Penicillamine, in ankylosing spondylitis, 122  
 Penicillin G, in articular cartilage, 828  
 Pentazocine, abuse of, 923, 925  
 Peptidoglycan, streptococcal, 260  
 Percodan therapy, in hepatic injury, 965  
 Pariarteritis nodosa, 949  
 Periarticular synovium, removal of, 1300  
 Pericardial tamponade, in JRA, 760-762  
 Pericardiocentesis, 761-762  
 Pericarditis, 1335  
 infectious, 761  
 Periodic acid Schiff reaction, 1340  
 Peripheral blood lymphocytes  
 antirheumatic drugs and, 907-916  
 blastogenic transformation of, 509  
 mitogenic responses of to autologous cells, synovial fluid, and phytohemagglutin, 526-529  
 responsiveness of to synovial fluid cells, 525  
 transformation of by autologous synovial fluid lymphocytes, 523-530  
 Peripheral neuritis, 1335  
 Peritoneal dialysis, gold toxicity and, 936-938  
 Peritoneal immunoglobulin light chain, in primary amyloidosis, 755-758  
 Perivascular cells, in transitional area, 13  
 Perivascular cellular accumulations  
 cell counts in, 3-5  
 electron microscope findings in rheumatoid synovitis, 3  
 lymphocytes in, 6-8  
 perivascular collections in, 8  
 in rheumatoid synovitis, 3-4  
 three types of, 8  
 PGE, *see* Prostaglandin E<sub>2</sub>  
 PGs, *see* Proteoglycans  
 PHA, *see* Phytohemagglutinin  
 Phagocytosis  
 in familial Mediterranean fever, 619  
 reduction of, 73-77  
 PHA mitogens  
 response of whole blood cultures to, 1273  
 in SLE, 89  
 Phenylbutazone, lymphocytes and, 907, 909-915  
 Phosphoribosylpyrophosphate content, benzboromarone and, 184, 188-189  
 PHS, *see* Pooled human serum  
 Phytohemagglutination, antibody identification in, 575  
 Phytohemagglutinin, in amyloidosis, 173  
 lymphocyte response in, 509-511, 525-527, 875, 912-913, 1266-1267  
 in RA, 720  
 Pima Indians, HLA-B27 antigen and sacroiliitis in, 791  
 Pi phenotypes, in RA, 627  
 Plant thorn synovitis, 825  
 Plasma, fibrinogen levels in, 1240  
 Plasma cells, in rheumatoid synovitis, 8  
 Plasma cells, infiltration of rheumatoid synovium by, 1  
 Plasmacytomas, hemarthrosis and, 99  
 Pleuritis, 1335  
 PMF, *see* Progressive massive fibrosis  
 PML, *see* Progressive multifocal leukoencephalopathy  
 PMN, *see* Polymorphonuclear leukocytes  
 Pneumoconiosis  
 in coal miners, 731-735  
 "complicated," 732  
 frequency and severity of, 733-734  
 Pokeweed mitogen  
 antilymphocyte antibody activity of, in SLE, 1266-1268  
 lymphocyte responses to, 509, 512-513  
 Polyarteritis, drug abuse and, 923  
 Polyarthritis  
 carcinomatous, 953-957  
 in childhood, 808  
 Polychondritis, relapsing, 32, 229  
 Polydeoxyribonucleotide, antibodies to, 867-872  
 Polyinosinic-polycytidyllic acid, interferon and, 1315-1319  
 Polymixin B, in articular cartilage, 828  
 Polymorphonuclear leukocytes, 73  
 in adjuvant arthritis, 1340-1345  
 chemotaxis of, 825-826  
 CPPD crystals in, 95  
 lysosomal enzymes in, 830  
 phagocytic capacity of, 77  
 release of proteolytic enzymes from, 68-69  
 in SLE, 73  
 Polymyalgia rheumatica, 32  
 joint imaging in, 815  
 Polymyositis  
 antinuclear antibody in, 830  
 arthralgias in, 243, 245  
 deforming arthritis of hands in, 243-248  
 diagnosis of, 245  
 osteoporosis and, 244  
 "overlap syndrome" in, 245-246, 248  
 Polymyositis-like syndrome, hypothyroidism as, 1363-1366  
 Polyriboadenylic acid, antibody binding of in SLE, 705-709  
 Pooled human serum, 532  
 mixed leukocyte reaction in, 534-535  
 rheumatoid, lymphocyte response in, 536  
 PPD antigens, in SLE, 89  
 PPH, *see* Procollagen proline hydroxylase  
 Prednisolone, virus antigens and, 1274  
 Prednisone, in ankylosing spondylitis, 111  
 Prednisone-azathioprine, in lupus nephritis treatment, 693-698  
 Pregnancy  
 azaribine and, 28  
 rheumatoid arthritis and, 602  
 Pregnancy-associated serum factor, 815-816  
 Primary amyloidosis, 174-175  
*see also* Amyloidosis  
 immunoglobulin light chain in, 755-758  
 Progressive systemic sclerosis, nasal septum perforation in, 119-121  
 Progressive massive fibrosis, 732  
 Progressive multifocal leukoencephalopathy, 267  
 Progressive systemic sclerosis, 216, 246  
*see also* Scleroderma  
 counterimmunoelectrophoresis in, 574, 578  
 epidermal epithelial cell growth in, 969-970  
 HLA-D antigen in, 794  
 lymphocyte response to mitogens in, 875-881  
 skeletal muscle abnormalities in, 807-808  
 Proliferative lesion, in RA, 68-71  
<sup>14</sup>C-Proline, determination of in scleroderma fibroblasts, 893  
<sup>3</sup>H-Proline, in cartilage explants, 206  
<sup>3</sup>H-Proline-labeled collagen, in rabbit articular cartilage, 204  
 Pronase, 927  
 Properdin factors, in JRA, 161-166  
 Prophylactic colchicine therapy, in familial Mediterranean fever, 618-621  
 Prostaglandin E<sub>2</sub>, 31  
 rheumatoid synovial tissue and, 70  
 Prostaglandin synthesis, corticosteroid inhibition of, 818-819  
<sup>125</sup>I Protein A, IgG antilymphocyte antibody detection of, 1261-1268  
 Protein AA, in murine amyloid, 822-823  
 Protein adsorption, to monosodium urate crystals, 805  
 Protein SAA, in murine amyloid, 822-823  
 Proteoglycans, 1310-1314  
 amino acid composition of, 212  
 from bovine cartilage, 1312  
 cartilage, *see* Cartilage proteoglycans  
 chondroitin sulfate chains of, 214  
 constituents of, 209

depletion of from articular cartilage, 68  
enzymic digestion and, 1288  
extract preparation from, 1288, 1310  
guanidinium in extraction of, 212-213  
hyaluronate-binding region on, 1308-1314  
isolation of, 1309-1310  
in normal and osteoarthritic knee cartilage, 209-214  
proteolytic degradation of, 1289-1290  
synovial fluid and, 772  
synthesis of in articular cartilage, 918-921  
Proteolytic enzymes, in synovial tissue extracts, 1289-1291  
Prothrombin time, lupus anticoagulant and, 1244  
Protocollagen proline hydroxylase, 891-892  
PRPP, see Phosphoribosylpyrophosphate  
Pseudogout, 32  
  crystal shedding and, 93-97  
  defined, 93  
  indomethacin and, 95  
  lavage procedure in, 94  
  parathyroidectomy and, 96  
  postoperative acute attack of, 97  
  predisposing events in, 96  
Pseudomonas aeruginosa, 169  
Psoriasis  
  ankylosing spondylitis and, 660  
  chronic peripheral arthritis and, 662  
  connective tissue activating substance and, 611  
  DNA content of, 612  
  genetic factors in, 663  
  HLA antigens in, 611  
  <sup>99m</sup> Technetium diphosphonate uptake in, 607-612  
Psoriatic arthritis, 661, 663  
  *see also* Azaribine  
  azaribine in, 21-28  
  Down's syndrome and, 651  
  6-mercaptopurine in, 28  
  nasal septum perforation in, 119-121  
PSS, *see* Progressive systemic sclerosis  
Pulmonary disease, maximal midexpiratory flow rates in, 624-626  
Pulmonary embolus, following patellar scraping, 99-100  
Pulmonary fibrosis, hypertrophic osteoarthropathy and, 643  
Pulmonary involvement, in mixed connective tissue disease, 801  
Pulmonary lesions, in RA patients, 623  
Pulmonary osteoarthropathy, hypertrophic, *see* Hypertrophic pulmonary osteoarthropathy  
Purine biosynthesis, benzboromarone and, 189  
Purine phosphoribosyltransferase, benzboromarone and, 184  
Purine synthesis, benzboromarone in, 183  
Purpura, *see* Henoch-Schönlein purpura  
PVP hemagglutination test, in rat chondrocyte antigen studies, 224  
PWM in SLE, 89  
  *see also* Pokeweed mitogen

## Q

Quinidine, hemarthrosis and, 100

## R

RA, *see* Rheumatoid arthritis  
Rabbit articular cartilage, metabolic changes in due to inflammation, 199-207  
Rabbit knee joint, 770-771  
  carageenin injection in, 1287  
  proteolytic enzymes in, 1287-1293  
Rabbits, osmotic acid treatment in, 740  
Rabbit synovial cells  
  acid phosphatase and, 1292  
  explant cultures of, 584-586

fibroblast population of, 588  
fine structure analysis of, 581-591  
hyaluronic acid production and, 587  
inflammatory response in, 739-740  
membrane receptor studies and, 586-588  
monolayer cultures of, 587-588  
rosette forming cells and, 582-584, 589-591  
Radiogold, intracellular distribution of, 927-931  
Radionuclide imaging, in <sup>99m</sup>technetium diphosphonate uptake, 608  
RAI, *see* Ritchie articular index  
RAP, *see* Rheumatoid arthritis precipitin  
Rat chondrocyte  
  antigen profile of, 223-230  
  hemagglutinating bodies produced by, 225  
  in tissue culture, 228  
Rat liver xanthine oxidase activity, benzboromarone in, 183  
Raynaud's phenomenon, 243-244  
  biofeedback in, 795  
  polymyositis and, 246-247  
  vinyl chloride and, 809  
Reactive arthritis, 664-665  
Regional Medical Programs Arthritis Conference, 645  
Reiter's disease, 660-661, 665, 747  
  adjuvant arthritis and, 1339  
  following urethritis, 664  
  HLA antigens and, 664, 883  
postdysenteric, 664  
  T mycoplasma antibody and, 1332  
Relapsing polychondritis  
  arthropathy and, 191-194  
  autoimmune mechanism in, 229  
  case report in, 192-193  
  defined, 191  
  RA and, 193  
Renal disease, in SLE, 196, 806  
Renal tubular defect, in gout, 828-829  
Research and training programs, 32-33  
Research grants, 32  
Rheumatic diseases  
  chronic effects of, 907  
  federal support for research in, 30  
  HLA antigens and, 658-659  
  inheritance of, 656-665  
  oral contraceptives and, 602  
  perforation of nasal septum in, 119-121  
  "recent," 32  
  susceptibility to, 656-665  
  uniform database for, 645-648  
Rheumatic fever, HLA antigens and, 658-659  
Rheumatoid arthritis  
  *see also* Rheumatoid factor  
  agammaglobulinemia and, 555  
  altered lymphocyte reactivity in, 509-515  
  antibodies to native and denatured collagens in, 613-616  
  antibody-dependent cell-mediated cytotoxicity in, 725-729  
  antibody-mediated immunity in, 555  
  anti-gamma globulins in, 613  
  antigen-antibody complexes in, 613  
  antinuclear antibodies in, 712  
  antisera and fluorochrome conjugates in, 556  
  antitrypsin phenotypes in, 627  
  articular surface erosion in, 769  
  aspirin in, 155-160  
  avian reovirus arthritis as model of, 830  
  azathioprine in, 795  
  blood gold concentrates in, 598  
  blood histidine concentration in, 593  
  blood L lymphocytes in, 802-803  
  carpo/metacarpal ratio in, 939-944  
  cell-mediated immunity to IgG in, 828  
  cellular hypersensitivity in, 539-543  
  chloroquine in, 113-114

chrysotherapy in, 1321-1327  
circulating anticollagen and anti-IgG autoantibodies in, 539  
in coal miners, 731-735  
coexistence with ankylosing spondylitis, 111-114  
combination therapy in, 677-681  
concanavallin A and, 720-724  
corticosteroid treatment in, 1331-1335  
counterimmunolectrophoresis in, 574, 578  
cryoglobulins in, 103  
cutaneous vessel immune deposits in, 15-19  
cyclophosphamide in, 563-572  
deficient cell-mediated immune responses in, 807  
degenerative joint disease in, 627  
delayed immune response in, 564-565, 570-571  
dermal vessels in, 16  
disease activity measures in, 565-567  
in dogs, 970-971  
erythrocyte sedimentation rate in, 566-567  
etiology of, 555  
extraarticular vasculitis in, 18  
Felty's syndrome in, 150  
fenoprofen in, 933-935  
free blood amino acid in, 593  
functional test in, 1278-1280  
gamma globulin denaturation in, 593-599  
gold salts in, 113-114, 796, 927, 1321  
hemagglutination enhancement test and, 614  
histidine, cystine, and copper concentrations in, 597-599  
humoral antibody response in, 564  
hypertrophic osteoarthropathy and, 639-644  
ibuprofen in, 791  
ICF in, 1237  
identification of B and T lymphocytes in, 556  
IgG galactose deficiency in, 813  
IgG immunity in, 828  
immune complexes in, 788  
immunofluorescence microscopy in, 557  
immunologic mechanisms in, 223  
inflammatory process in, 68  
intracellular collagen at pannus/cartilage junction in, 801-802  
joint destruction in, 199  
juvenile, *see* Juvenile rheumatoid arthritis  
ketoprofen in, 791  
LDAC and, 142-149  
leg ulcers in, 18  
leukocyte responses to, 798  
Levamisole in, 807  
lungs in, 732  
lymphocytes in, 523, 720-724  
lymphocytotoxicity in, 133-140  
lymphoid hyperplasia in, 523  
lymphokines in, 70  
measurements in, 1278-1284  
mixed leukocyte reaction in, 532-537  
morning stiffness in, 1281-1282  
*Mycoplasma* strains in, 649-650  
nailfold capillary microscopy in, 1370-1371  
Naproxen with aspirin in, 677-681  
nasal septum perforation in, 119-121  
neoplasia in, 1256-1260  
obstructive pulmonary disease in, 623-627  
organic brain syndrome and, 1333-1337  
parenchymal pulmonary lesions in, 623  
pericarditis and, 760  
Pi phenotypes in, 627  
pleuropulmonary manifestations in, 623  
pneumoconiosis and, 731-735  
polyarthritis and, 953  
polymorphonuclear cells in, 774  
pregnancy and, 602  
primary humoral immune response in, 570  
proliferative lesion in, 68-71  
relapsing polychondritis and, 193  
seronegative, 814  
seropositive, 16  
serum antibody vs cell-associated antigen in, 711-718  
serum immunoglobulins in, 570, 731-735  
Sjögren's syndrome and, 216, 712  
skin immunoreactants in, 17  
sodium aurothiomalate in, 802  
subtypes of, 711-712  
sural nerve biopsies in, 823  
synovial collagenase and, 69  
synovial fluid in, 744  
synovial inflammation in, 769  
synovial membrane in, 581, 737  
synovitis in, 539  
thrombocytosis in, 793  
T-lymphocyte predominance in, 555-561  
vasculitis and, 15-19, 1237  
wrist involvement in, 112-113, 939-944  
wrist prosthesis in, 828  
X-ray changes in, 568-569  
Rheumatoid arthritis precipitin, 216, 714-715, 787  
as antibody, 717  
characterization of, 713  
immunoglobulin nature of, 716  
prevalence of in connective tissue diseases, 713-714  
RA antigen and, 220-221  
rheumatoid factor and, 219-220  
in synovial fluid, 718  
Rheumatoid arthritis precipitin antigen, protein molecule as, 717  
Rheumatoid disease, coagulation abnormalities in, 1237-1241  
*see also* Rheumatoid arthritis; Rheumatoid factor  
Rheumatoid factor  
*see also* Rheumatoid arthritis  
in acute bacterial endocarditis, 887-890  
in coal miners, 732  
in choroid plexus, 1336  
cyclophosphamide and, 569-570  
IgG interactions with, 827  
IgM type, 661  
inconstancy of, 605  
oral contraceptives and, 604  
organic brain syndrome and, 1335  
in women, 602-606  
Rheumatoid patients, cathepsin D in tissues of, 1295-1305  
Rheumatoid pericarditis, 760-762  
Rheumatoid serum, mixed leukocyte reaction and, 535-536  
Rheumatoid synovial cells, cell growth inhibitor in, 823  
Rheumatoid synovial collagenase, release and activation of, 809  
Rheumatoid synovial membrane, immunoreactive cells in, 1-13  
Rheumatoid synovitis  
blast cells in transitional areas of, 5-6  
cell counts in, 3-5  
electron microscope findings in perivascular cellular accumulations of, 3  
fibroblast degeneration in, 10  
light microscope findings in sublining area of, 2-3  
lymphoid cell macrophage contact in transitional areas of, 6  
perivascular cellular collection in, 3-4  
T and B cells in, 8-10  
vasculitis in, 18  
Rheumatoid synovium  
cell specimens in, 557-559  
cellular immune response in, 10  
colchicine and, 69  
immunologic responses of, 1  
living cells from, 70  
lymphocytes and plasma cells in, 1, 6-8  
prostaglandin synthesis by, 70, 818-819

sublining area of, 6  
T and B lymphocytes in, 556-559  
transitional areas in, 8  
Rheumatoid ulcers, 18-19  
Rheumatoid vasculitis, 15-19, 950-951  
Rheumatologists, consultant, in U.S., 56-58  
Rheumatology, organizations involved in, 655  
Rheumazahl index, 1282  
Rh factor negative, 814  
Ribonucleoprotein, nuclear, 574  
Ritchie articular index, 1278-1279, 1281, 1283-1284  
RNA-DNA hybridization, in detection of *Erysipelothrix* arthritides, 38-42  
Rosette forming cells, in rabbit synovial membrane, 582-584, 589-591  
RP, *see* Relapsing polychondritis  
Rubella  
arthritis and, 1317  
lymphocyte response to, 1271  
research in, 31

**S**

Sacroiliac, *Mycobacterium intracellulare* and, 777-780  
Sacroiliitis, 663  
HLA antigens in, 661  
in Pima Indians, 791  
Salicylate-induced hepatic injury, 964-965  
Salicylates, liver enzymes and, 267-268  
Salmonella arthritis, 665  
Sarcoidosis, 660  
SATM, *see* Sodium aurothiomalate  
SCAT, *see* Sheep cell agglutination tests  
Schiff reaction, 1340  
Scleroderma  
*see also* Progressive systemic sclerosis  
blood L lymphocytes in, 802-803  
capillary microscopy in, 1368  
collagen synthesis in, 816, 895  
complement-fixing antinuclear antibody in, 857-860  
eosinophilia and, 792  
fibroblasts in, 817  
mandibular bone erosion and, 1371  
skin collagen biosynthesis in, 899-900  
skin elasticity and colchicine in, 832  
vinyl chloride and, 809  
Scleroderma Club, 36  
Scleroderma fibroblasts, connective tissue synthesis by, 891-900  
Sclerodermatous skin organ cultures, 804  
Sclerosis, pentazocine and, 925  
Sephadex G-200 fractions, in synovial fluid LDAC inhibition, 147  
Sephadex gel filtration, in LDAC studies, 143-144  
Septic arthritis, 65  
Serum dilution studies, in SLE, 74  
Serum immunoglobulins, in RA, 731-735  
Serum salicylate  
in JRA, 115-118  
in mixed leukocyte reaction, 537  
Sexual coupling, and chondromalacia patellae, 637-638  
SF, *see* Synovial fluid  
SGOT (serum glutamic oxaloacetic transaminase)  
in C2 deficiency, 518-519  
in Felty's syndrome, 153  
serum salicylate and, 115-118  
in Still's disease, 234  
SGPT (serum glutamic pyruvic transaminase)  
in C2 deficiency, 518-519  
serum salicylate and, 115-118  
Sheep cell agglutination tests, cyclophosphamide and, 569-570  
*Shigella flexneri* dysentery, 664

Sjögren's syndrome  
antibodies to nuclear antigens in, 574  
antinuclear antibodies in, 712  
autoantibody differentiation and characterization in, 216-222  
cellular antigens reacting with, 218-219  
complexity of, 216-217  
counterimmunoelectrophoresis in, 578  
defined, 216  
dysproteinemia and, 1336  
Felty's syndrome and, 150  
HLA antigens in, 947  
HLA-B8 and, 883-886  
lymphocyte proliferation in, 811-812  
nuclear ribonucleoprotein in, 576-577  
organic brain syndrome and, 1334-1336  
precipitins in, 218-220  
rheumatoid factor in, 218  
Skeletal muscle abnormalities, in progressive systemic sclerosis, 807-808  
Skin  
hyperextensibility of, 765  
immune deposits in, in SLE, 1249-1254  
Skin capillary abnormalities, vinyl chloride and, 809  
Skin immunoreactants, in RA, 17  
Skin lesions  
in C2 deficiency, 521  
in extraarticular vasculitis, 18  
Skin vessels, immunofluorescence of, 18  
Skin-window test, in colchicine therapy, 620-621  
SLE, *see* Systemic lupus erythematosus  
SLE-like disease, C8 component in, 803  
Smallpox, arthritis and, 1317  
Smoking, maximal midexpiratory flow rates in, 624-625  
Sodium acetate extract, proteoglycans and, 210  
Sodium aurothiomalate, 907  
lymphocytes and, 909  
in RA, 802  
Sodium meclofenamate, 907  
Sodium warfarin therapy  
in hemarthrosis, 98-101  
quinidine and, 100  
vitamin K and, 101  
Spine, ankylosing hyperostosis of, 818  
Spleen, gold levels in, 1368-1369  
Spleen cells, transfer of in NZB/W mice, 1353-1357  
Splenectomy, in Felty's syndrome, 150, 153  
Spondylitis, ankylosing, *see* Ankylosing spondylitis  
SS, *see* Sjögren's syndrome  
*Staphylococcus albus*, 618  
*Staphylococcus aureus*, endocarditis due to, 887  
Sternomanubrial joint disease, 1372-1373  
Steroid osteopenia, reduction of, 800  
Steroid pseudorheumatism, 1335  
Steroids, *see* Corticosteroids  
Still's disease, 232-241, 955  
ankylosis in, 235, 240-241  
hands and wrist in, 235-236  
JRA and, 240  
SGOT and SGPT levels in, 234  
symptoms in, 233  
Streptococcal cell wall induced arthritis, 260-264  
Streptococcal peptidoglycan  
immunochemistry of, 260-261  
polysaccharide complex in, 261  
Subacute bacterial endocarditis, arthritis of, 813-814  
Superoxide radical, cartilage proteoglycan degradation by, 799  
Sydenham's chorea, possible cause of, 803  
Synovial cathepsin D, 738  
Synovial cells  
in glycolysis or hyaluronic acid formation, 70  
rabbit, *see* Rabbit synovial cells  
Synovial collagenase, in RA, 69

Synovial fibroblasts, hyaluronic acid from, 1315-1319

Synovial fluid

CPPD crystals in, 93, 95

enzymes in, 203

human, *see* Human synovial fluid

hydroxyapatite-like crystals in, 821

immunologic tests for, 528

in JRA, 161-166

lactoferrin-to-lysozyme ratio in, 789

LDAC and, 138, 142-149

lymphoblasts and monocytes in, 745-747

lymphokine-like substances in, 10

MIIF in, 10-13

peripheral blood lymphocytes incubated from, 529

proteoglycan breakdown products in, 772

in relapsing polychondritis, 193

in Whipple's disease, 820

Synovial fluid lymphocytes

mitogenicity of for autologous peripheral blood

lymphocytes, 530

in peripheral blood lymphocyte transport, 523-530

RA and, 523

Synovial fluid viscosity, measurement of, 1358-1361

Synovial membrane

electron microscope studies of, 1-2

joint destruction and, 737

light microscopy studies of, 634

rheumatoid, *see* Rheumatoid synovial membrane

in RA, 581

rosette forming cells in, 582-584

samples of, 1-2

in Whipple's disease, 820

Synovial small vessels, permeability of, 800

Synovial tissues

cathepsin D secretion and localization in, 1295-1305

nucleic acid hybridization in, 38-42

T-lymphocyte predominance in, 555-561

Synovitis

in degenerative joint disease, 813

erotic, 256-264

immune, *see* Immune synovitis

plant thorn, 825

in RA, 539-543

Synovium

in experimental hemarthrosis, 60

histologic appearance of, 1298

plastic debris in, 793

rheumatoid, *see* Rheumatoid synovium

T and B cells in, 10-13

Systemic amyloidosis, humoral and cellular immune abnormalities in, 173-180

Systemic lupus erythematosus, 32, 75-76

*see also* Lupus erythematosus

abnormal lymphocyte cell cycle kinetics in, 827-828

absent factor II in, 79-81

adrenal insufficiency in, 249-252

allergy in, 669-673

amyloidosis and, 249-252

antibodies to DNA (nDNA) in, 867-870

antibodies to nuclear antigens in, 574-575

antibody avidity in, 806

antibody binding of polyriboadenyllic acid in, 705-709

antibody to nuclear RNP detection in, 574

anticomplementary activity of serum in, 76

anti-DNA antibody in diagnosis of, 247

antilymphocyte antibodies in, 821

anti-nDNA antibodies in, 815, 867, 1253

antinuclear antibody in, 1245

antinuclear antibody in diagnosis of, 247

anti-RNA antibody in, 1267

ascites as major manifestation of, 782-785

aspirin in, 155-160

autoantibodies in, 88, 90

autologous mixed lymphocyte reactivity of blood cells in, 824-825

as best characterized human immune complex disease, 88

black vs white patients in, 130-131

B-lymphocyte activity in, 790

brain scan and cerebral radionuclide angiogram diagnosis in, 826

C2 deficiency in, 517

calcinoses in, 247

case report in, 79

cell-mediated immunity in, 88, 1274-1275

circulating DNA in, 837

corticosteroid therapy in, 77, 79-81, 196-197

counterimmunoelectrophoresis in, 578

cutaneous vasculitis in, 814

dermatoglyphic study of, 83-86

discoid lesion and, 517-522

as disease of young women, 81

DNA-anti-DNA type, 669, 797

factor II defect in, 79-81

fibrinogen catabolism in, 195-198

fluorescent band skin test in, 792

hand deformity in, 248

hemorrhagic diathesis in, 79-80

hereditary C2 deficiency in, 517-522

histocompatibility antigens in, 129-131

HLA antigens in, 658-659

hydralazine therapy in, 122

IgG antilymphocyte antibodies in, 1261-1268

IgG galactose deficiency in, 813

as immune complex disease, 837

immune response in, 545-552

immune skin deposits in, 1249-1254

immunoblastic sarcoma and, 249-252

immunoglobulins in, 73, 670-671

immunologic studies in, 79-81

inflammatory disease in, 49

LDAC and, 142-149

low acetyl transferase activity in, 796

in lungs, 249-252

lupus anticoagulant in, 1244-1247

lupus band test in, 1249-1254

lymphocyte responsiveness in, 88-91, 805, 1271-1276

lymphocytotoxicity in, 100-103, 133-140, 817-818, 831, 844-849

lymphokine production in, 794

lysosomal enzyme reduction in, 73-77

Mexican-American vs Caucasian, 83

mitogen and antigen stimulation in, 89, 827-828

mitogen responses in, 547-550

mixed leukocyte cultures in, 546-549

monocyte identification in, 89

mononuclear cell isolation in, 89

nailfold capillary microscopy in, 1370

nasal septum perforation in, 119-121

neoplasia in, 1256-1260

nephritis and, 49

oral contraceptives and, 602-603

organic brain syndrome and, 1336

peripheral blood cell suppressor function in, 791

persisting serologic abnormalities in, 837-843

phagocytosis reduction in, 73-77

PHA mitogens in, 89

PPD antigens in, 89

precipitating antibodies vs nuclear antigens in, 808

pulmonary hemorrhage in, 812

PWM in, 89

quantitation of blood L lymphocytes in, 802-803

radioimmunoassay in, 801

relatives affected by, 700-703

renal disease and, 195, 806

renal histologic abnormalities in, 824

serum autoantibodies in, 801

serum  $\beta$ 2-microglobulin and, 968  
serum dilution in, 76  
serum salicylate concentrations in, 115-116  
SGOT level in, 158  
T-cell dysfunction in, 88-89  
thoracic duct drainage in, 814  
thumb hyperextension and subluxation in, 247  
twin studies in, 545-552  
Type C RNA virus-related protein antigen in, 809-811, 816

## T

T-cell dysfunction, in SLE, 88  
T-cell enumeration, in SLE, 89  
T-cell function, in amyloidosis, 173  
T-cell mitogen, 70  
T cells, *see* T lymphocytes  
 $^{99m}$ Tecnetium diphosphonate  
periarticular joint concentration with, 610-611  
periarticular uptake of, in psoriasis, 607-612  
Temporal arteritis, non-giant cell, 812  
Tenosynovitis, Still's disease and, 234  
Thermal denaturation  
histidine concentration in, 599  
of human gamma globulin, 593-599  
Thomas Report, 31  
Thrombocytosis, in RA, 793  
Thrombophlebitis, 1335  
Thymic factors, in NZB/W mice, 862-865  
Thymidine, tritiated, 907-916  
 $^3$ H-Thymidine, in articular cartilage metabolic changes, 199-204  
Thymocytes, autoimmunity suppression with, 345-347  
Thymosin  
in amyloidosis, 180  
in NZB/W mice, 862-865  
T lymphocytes  
in amyloidosis, 175-176  
and familial Mediterranean fever, 618  
lymphokines and, 10  
macrophages and, 8-10  
predominance of in RA, 555-561  
in rheumatoid synovitis, 8-13, 557-560  
serum antibodies against, 1328-1332  
Tobacco smoking, in obstructive pulmonary disease, 623-626  
Tolmetin, aspirin and, in JRA, 807  
"Total hand" infection, long-term effects of, 800  
Total hemolytic component, in JRA, 161-166  
Transaminase concentrations, in JRA, 115-118  
*see also* SGOT (serum glutamic oxaloacetic transaminase)  
Transitional areas  
fibroblast degeneration in, 6  
lymphoid cell-macrophage contact in, 6  
perivascular cells in, 13  
in rheumatoid synovitis, 5-8  
T and B lymphocytes in, 8-10  
Trapezioscapoid arthropathy, 833  
Triton X-100, 927, 931  
Tryphan blue cytotoxicity test, 224-227  
Tubuloreticular structures, in SLE lymphocyte twin studies, 546, 551-552  
Twin studies  
antigens in, 545  
in SLE, 545-552  
tubuloreticular structures in, 546, 551-552

## U

Ulcerative colitis, 660, 662  
HLA antigens and, 662  
Ultrasound B-scanning, 651

Uniform Database for Rheumatic Diseases, 645-647  
Urate, tubular transport of, 811  
Urethritis, Reiter's disease following, 664  
Uric acid excretion, benzboromarone and, 183  
Uricosuric drug, benzboromarone as, 183  
Uronic acid  
loss of in arthritic cartilage, 211  
recovery of, 212  
Uveitis, anterior nongranulomatous, 539-543

## V

Vaccinia  
arthritis and, 1317  
azathioprine and, 270  
Varicella, arthritis and, 1317  
Varicella-zoster virus antigens, immune response to, 1271, 1274  
Vasculitis  
cryoproteins in, 829  
development of, 19  
extraarticular, 18  
immune deposits in, 19  
in RA, 15-19, 1237, 1241  
rheumatoid, 15-19, 950-951  
in rheumatoid synovitis, 18  
skin immunoreactions and, 17  
skin lesions in, 15  
Ventricular tachycardia, 1373-1374  
Venulitis, cutaneous necrotizing, 945-949  
Veracruz period, pre-Columbian representation of Heberden's nodes in, 125-126  
Vinyl chloride, skin capillary abnormalities and, 809  
Vinyl chloride acro-osteolysis, resorption of mandible in, 971  
Viral hepatitis  
arthritis and, 1317  
drug abuse in, 923  
Viral RNA-directed DNA polymerase, 816  
Virus antigens  
lymphocyte response to, in SLE, 1271-1276  
prednisolone and, 1274  
Viscosity increment  
histidine and, 595-596  
of human gamma globulins, 595-596  
Vitamin D, in steroid osteopenia reduction, 800  
Vitamin K therapy, in hemarthrosis, 101

## W

Warfarin therapy, 98-101  
Wax D, adjuvanticity of, 259  
Wegener's granulomatosis, nasal septum perforation in, 119-121  
Whipple's disease, 820  
White blood cell pipette, in synovial fluid measurement, 1358-1361  
Women  
rheumatoid factor in, 602-606  
SLE in, 81  
Wrist  
in RA, 828, 939-944  
in Still's disease, 235-240  
swelling in ankylosing spondylitis, 112-113

## Y

Yersinia arthritis, 31-32  
Yersinia enterocolitica, 664-665

## Z

Zymosan, uptake of, 73

